1
|
Ibrahim JP, Dao N, Haque S, Phipps S, Whittaker MR, Kaminskas LM. Hydrogenated Soy Phosphatidylcholine Liposomes Stimulate Differential Expression of Chemokines And Cytokines by Rat Alveolar Macrophages In Vitro. J Pharm Sci 2024; 113:1395-1400. [PMID: 38460572 DOI: 10.1016/j.xphs.2024.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 02/29/2024] [Accepted: 03/01/2024] [Indexed: 03/11/2024]
Abstract
Liposomes are being developed as inhalable drug delivery systems, but concerns remain about their impact on the lungs. To better understand the impact of liposomes and their physicochemical properties on alveolar macrophages, the cytokine and chemokine expression profile of rat alveolar Nr8383 macrophages exposed to 0.1 and 1 mg/ml hydrogenated soy phosphatidylcholine (HSPC) liposomes was examined. Expression patterns varied considerably between liposomes in a concentration-dependent manner, with both anti- and pro-inflammatory chemokines/cytokines produced. Uncharged liposomes induce the greatest production of cytokines and chemokines, followed by PEGylated liposomes. The most significant increase in cytokine/chemokine expression was seen for IL-2 (up to 24-fold), IL-4 (up to 5-fold), IL-18 and VEGF (up to 10-fold), while liposome exposure significantly reduced MIP1 expression (5-fold). In summary, we demonstrate that liposome surface properties promote variable patterns of cytokine and chemokine secretion by alveolar macrophages. This suggests that the type of liposome employed may influence the type of immune response generated in the lung and by extension, dictate how inhaled liposomal nanomedicines affect the lungs response to inhaled toxicants and local infections.
Collapse
Affiliation(s)
- Jibriil P Ibrahim
- School of Biomedical Sciences, University of Queensland, Brisbane, 4072, Australia
| | - Nam Dao
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, 3052, Australia
| | - Shadabul Haque
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, 3052, Australia
| | - Simon Phipps
- Respiratory Immunology, QIMR Berghofer Medical Research Institute, Brisbane, 4006, Australia
| | - Michael R Whittaker
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, 3052, Australia
| | - Lisa M Kaminskas
- School of Biomedical Sciences, University of Queensland, Brisbane, 4072, Australia.
| |
Collapse
|
2
|
Ediriweera GR, Butcher NJ, Kothapalli A, Zhao J, Blanchfield JT, Subasic CN, Grace JL, Fu C, Tan X, Quinn JF, Ascher DB, Whittaker MR, Whittaker AK, Kaminskas LM. Lipid sulfoxide polymers as potential inhalable drug delivery platforms with differential albumin binding affinity. Biomater Sci 2024. [PMID: 38683548 DOI: 10.1039/d3bm02020g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2024]
Abstract
Inhalable nanomedicines are increasingly being developed to optimise the pharmaceutical treatment of respiratory diseases. Large lipid-based nanosystems at the forefront of the inhalable nanomedicines development pipeline, though, have a number of limitations. The objective of this study was, therefore, to investigate the utility of novel small lipidated sulfoxide polymers based on poly(2-(methylsulfinyl)ethyl acrylate) (PMSEA) as inhalable drug delivery platforms with tuneable membrane permeability imparted by differential albumin binding kinetics. Linear PMSEA (5 kDa) was used as a hydrophilic polymer backbone with excellent anti-fouling and stealth properties compared to poly(ethylene glycol). Terminal lipids comprising single (1C2, 1C12) or double (2C12) chain diglycerides were installed to provide differing affinities for albumin and, by extension, albumin trafficking pathways in the lungs. Albumin binding kinetics, cytotoxicity, lung mucus penetration and cellular uptake and permeability through key cellular barriers in the lungs were examined in vitro. The polymers showed good mucus penetration and no cytotoxicity over 24 h at up to 1 mg ml-1. While 1C2-showed no interaction with albumin, 1C12-PMSEA and 2C12-PMSEA bound albumin with KD values of approximately 76 and 10 μM, respectively. Despite binding to albumin, 2C12-PMSEA showed reduced cell uptake and membrane permeability compared to the smaller polymers and the presence of albumin had little effect on cell uptake and membrane permeability. While PMSEA strongly shielded these lipids from albumin, the data suggest that there is scope to tune the lipid component of these systems to control membrane permeability and cellular interactions in the lungs to tailor drug disposition in the lungs.
Collapse
Affiliation(s)
- Gayathri R Ediriweera
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - Neville J Butcher
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - Ashok Kothapalli
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - Jiacheng Zhao
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - Joanne T Blanchfield
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia
| | - Christopher N Subasic
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - James L Grace
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia
| | - Changkui Fu
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - Xiao Tan
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - John F Quinn
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia
- Department of Chemical Engineering, Monash University, Clayton, VIC, Australia
| | - David B Ascher
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, 4072, Australia
- Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia
| | - Michael R Whittaker
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, 3052, Australia
| | - Andrew K Whittaker
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD, 4072, Australia.
| | - Lisa M Kaminskas
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.
| |
Collapse
|
3
|
Bester B, Koslowa K, Gronau AC, Mietens A, Nowell C, Whittaker MR, Pilatz A, Wagenlehner F, Exintaris B, Middendorff R. The oxytocin antagonist cligosiban reduces human prostate contractility: Implications for the treatment of benign prostatic hyperplasia. Br J Pharmacol 2024. [PMID: 38676555 DOI: 10.1111/bph.16369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 02/22/2024] [Accepted: 02/27/2024] [Indexed: 04/29/2024] Open
Abstract
BACKGROUND AND PURPOSE With increasing life expectancy, benign prostatic hyperplasia (BPH) consequently affects more ageing men, illustrating the urgent need for advancements in BPH therapy. One emerging possibility may be the use of oxytocin antagonists to relax smooth muscle cells in the prostate, similar to the currently used (although often associated with side effects) α1-adrenoceptor blockers. EXPERIMENTAL APPROACH For the first time we used live-imaging, combined with a novel image analysis method, to investigate the multidirectional contractions of the human prostate and determine their changes in response to oxytocin and the oxytocin antagonists atosiban and cligosiban. Human prostate samples were obtained and compared from patients undergoing prostatectomy due to prostate cancer as well as from patients with transurethral resection of prostate tissue due to severe BPH. KEY RESULTS The two cohorts of tissue samples showed spontaneous multidirectional contractions, which significantly increased after the addition of oxytocin. Different to atosiban, which showed ambiguous effects of short duration, only long-acting cligosiban reliably prevented, as well as counteracted, any contractile oxytocin effect. Furthermore, cligosiban visibly reduced not only oxytocin-induced contractions, but also showed intrinsic activity to relax prostatic tissue. CONCLUSION AND IMPLICATIONS Thus, the oxytocin antagonist cligosiban could be an interesting candidate in the search for novel BPH treatment options.
Collapse
Affiliation(s)
- Beatrix Bester
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| | - Kristina Koslowa
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| | - Ann-Catherine Gronau
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| | - Andrea Mietens
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| | - Cameron Nowell
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia
| | - Michael R Whittaker
- Drug Discovery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia
| | - Adrian Pilatz
- Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig-University, Giessen, Germany
| | - Florian Wagenlehner
- Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig-University, Giessen, Germany
| | - Betty Exintaris
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, Victoria, Australia
| | - Ralf Middendorff
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| |
Collapse
|
4
|
Hussein M, Mahboob MBH, Tait JR, Grace JL, Montembault V, Fontaine L, Quinn JF, Velkov T, Whittaker MR, Landersdorfer CB. Providing insight into the mechanism of action of cationic lipidated oligomers using metabolomics. mSystems 2024:e0009324. [PMID: 38606960 DOI: 10.1128/msystems.00093-24] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 03/25/2024] [Indexed: 04/13/2024] Open
Abstract
The increasing resistance of clinically relevant microbes against current commercially available antimicrobials underpins the urgent need for alternative and novel treatment strategies. Cationic lipidated oligomers (CLOs) are innovative alternatives to antimicrobial peptides and have reported antimicrobial potential. An understanding of their antimicrobial mechanism of action is required to rationally design future treatment strategies for CLOs, either in monotherapy or synergistic combinations. In the present study, metabolomics was used to investigate the potential metabolic pathways involved in the mechanisms of antibacterial activity of one CLO, C12-o-(BG-D)-10, which we have previously shown to be effective against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300. The metabolomes of MRSA ATCC 43300 at 1, 3, and 6 h following treatment with C12-o-(BG-D)-10 (48 µg/mL, i.e., 3× MIC) were compared to those of the untreated controls. Our findings reveal that the studied CLO, C12-o-(BG-D)-10, disorganized the bacterial membrane as the first step toward its antimicrobial effect, as evidenced by marked perturbations in the bacterial membrane lipids and peptidoglycan biosynthesis observed at early time points, i.e., 1 and 3 h. Central carbon metabolism and the biosynthesis of DNA, RNA, and arginine were also vigorously perturbed, mainly at early time points. Moreover, bacterial cells were under osmotic and oxidative stress across all time points, as evident by perturbations of trehalose biosynthesis and pentose phosphate shunt. Overall, this metabolomics study has, for the first time, revealed that the antimicrobial action of C12-o-(BG-D)-10 may potentially stem from the dysregulation of multiple metabolic pathways.IMPORTANCEAntimicrobial resistance poses a significant challenge to healthcare systems worldwide. Novel anti-infective therapeutics are urgently needed to combat drug-resistant microorganisms. Cationic lipidated oligomers (CLOs) show promise as new antibacterial agents against Gram-positive pathogens like methicillin-resistant Staphylococcus aureus (MRSA). Understanding their molecular mechanism(s) of antimicrobial action may help design synergistic CLO treatments along with monotherapy. Here, we describe the first metabolomics study to investigate the killing mechanism(s) of CLOs against MRSA. The results of our study indicate that the CLO, C12-o-(BG-D)-10, had a notable impact on the biosynthesis and organization of the bacterial cell envelope. C12-o-(BG-D)-10 also inhibits arginine, histidine, central carbon metabolism, and trehalose production, adding to its antibacterial characteristics. This work illuminates the unique mechanism of action of C12-o-(BG-D)-10 and opens an avenue to design innovative antibacterial oligomers/polymers for future clinical applications.
Collapse
Affiliation(s)
- Maytham Hussein
- Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia
- Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
| | - Muhammad Bilal Hassan Mahboob
- Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Jessica R Tait
- Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - James L Grace
- Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Véronique Montembault
- Institut des Molécules et Matériaux du Mans, UMR 6283 CNRS-Le Mans Université, Le Mans, France
| | - Laurent Fontaine
- Institut des Molécules et Matériaux du Mans, UMR 6283 CNRS-Le Mans Université, Le Mans, France
| | - John F Quinn
- Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Department of Chemical and Biological Engineering, Faculty of Engineering, Monash University, Clayton, Victoria, Australia
| | - Tony Velkov
- Department of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia
- Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
| | - Michael R Whittaker
- Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Cornelia B Landersdorfer
- Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| |
Collapse
|
5
|
Abdallah M, Lin L, Styles IK, Mörsdorf A, Grace JL, Gracia G, Landersdorfer CB, Nowell CJ, Quinn JF, Whittaker MR, Trevaskis NL. Impact of conjugation to different lipids on the lymphatic uptake and biodistribution of brush PEG polymers. J Control Release 2024:S0168-3659(24)00185-8. [PMID: 38513730 DOI: 10.1016/j.jconrel.2024.03.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 02/28/2024] [Accepted: 03/16/2024] [Indexed: 03/23/2024]
Abstract
Delivery to peripheral lymphatics can be achieved following interstitial administration of nano-sized delivery systems (nanoparticles, liposomes, dendrimers etc) or molecules that hitchhike on endogenous nano-sized carriers (such as albumin). The published work concerning the hitchhiking approach has mostly focussed on the lymphatic uptake of vaccines conjugated directly to albumin binding moieties (ABMs such as lipids, Evans blue dye derivatives or peptides) and their subsequent trafficking into draining lymph nodes. The mechanisms underpinning access and transport of these constructs into lymph fluid, including potential interaction with other endogenous nanocarriers such as lipoproteins, have largely been ignored. Recently, we described a series of brush polyethylene glycol (PEG) polymers containing end terminal short-chain or medium-chain hydrocarbon tails (1C2 or 1C12, respectively), cholesterol moiety (Cho), or medium-chain or long-chain diacylglycerols (2C12 or 2C18, respectively). We evaluated the association of these materials with albumin and lipoprotein in rat plasma, and their intravenous (IV) and subcutaneous (SC) pharmacokinetic profiles. Here we fully detail the association of this suite of polymers with albumin and lipoproteins in rat lymph, which is expected to facilitate lymph transport of the materials from the SC injection site. Additionally, we characterise the thoracic lymph uptake, tissue and lymph node biodistribution of the lipidated brush PEG polymers following SC administration to thoracic lymph cannulated rats. All polymers had moderate lymphatic uptake in rats following SC dosing with the lymph uptake higher for 1C2-PEG, 2C12-PEG and 2C18-PEG (5.8%, 5.9% and 6.7% dose in lymph, respectively) compared with 1C12-PEG and Cho-PEG (both 1.5% dose in lymph). The enhanced lymph uptake of 1C2-PEG, 2C12-PEG and 2C18-PEG appeared related to their association profile with different lipoproteins. The five polymers displayed different biodistribution patterns in major organs and tissues in mice. All polymers reached immune cells deep within the inguinal lymph nodes of mice following SC dosing. The ability to access these immune cells suggests the potential of the polymers as platforms for the delivery of vaccines and immunotherapies. Future studies will focus on evaluating the lymphatic targeting and therapeutic potential of drug or vaccine-loaded polymers in pre-clinical disease models.
Collapse
Affiliation(s)
- Mohammad Abdallah
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Lihuan Lin
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Ian K Styles
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Alexander Mörsdorf
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - James L Grace
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Gracia Gracia
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Cornelia B Landersdorfer
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Cameron J Nowell
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia
| | - John F Quinn
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia; Department of Chemical Engineering, Faculty of Engineering, Monash University, Clayton, VIC, Australia
| | - Michael R Whittaker
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
| | - Natalie L Trevaskis
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia; Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
| |
Collapse
|
6
|
Abdallah M, Lin L, Styles IK, Mörsdorf A, Grace JL, Gracia G, Nowell C, Quinn JF, Landersdorfer CB, Whittaker MR, Trevaskis NL. Functionalisation of brush polyethylene glycol polymers with specific lipids extends their elimination half-life through association with natural lipid trafficking pathways. Acta Biomater 2024; 174:191-205. [PMID: 38086497 DOI: 10.1016/j.actbio.2023.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 11/08/2023] [Accepted: 12/04/2023] [Indexed: 12/21/2023]
Abstract
Polymeric prodrugs have been applied to control the delivery of various types of therapeutics. Similarly, conjugation of peptide therapeutics to lipids has been used to prolong systemic exposure. Here, we extend on these two approaches by conjugating brush polyethylene glycol (PEG) polymers with different lipid components including short-chain (1C2) or medium-chain (1C12) monoalkyl hydrocarbon tails, cholesterol (Cho), and diacylglycerols composed of two medium-chain (2C12) or long-chain (2C18) fatty acids. We uniquely evaluate the integration of these lipid-polymers into endogenous lipid trafficking pathways (albumin and lipoproteins) and the impact of lipid conjugation on plasma pharmacokinetics after intravenous (IV) and subcutaneous (SC) dosing to cannulated rats. The IV and SC elimination half-lives of Cho-PEG (13 and 22 h, respectively), 2C12-PEG (11 and 17 h, respectively) and 2C18-PEG (12 h for both) were prolonged compared to 1C2-PEG (3 h for both) and 1C12-PEG (4 h for both). Interestingly, 1C2-PEG and 1C12-PEG had higher SC bioavailability (40 % and 52 %, respectively) compared to Cho-PEG, 2C12-PEG and 2C18-PEG (25 %, 24 % and 23 %, respectively). These differences in pharmacokinetics may be explained by the different association patterns of the polymers with rat serum albumin (RSA), bovine serum albumin (BSA) and lipoproteins. For example, in pooled plasma (from IV pharmacokinetic studies), 2C18-PEG had the highest recovery in the high-density lipoprotein (HDL) fraction. In conclusion, the pharmacokinetics of brush PEG polymers can be tuned via conjugation with different lipids, which can be utilised to tune the elimination half-life, biodistribution and effect of therapeutics for a range of medical applications. STATEMENT OF SIGNIFICANCE: Lipidation of therapeutics such as peptides has been employed to extend their plasma half-life by promoting binding to serum albumin, providing protection against rapid clearance. Here we design and evaluate innovative biomaterials consisting of brush polyethylene glycol polymers conjugated with different lipids. Importantly, we show for the first time that lipidated polymeric materials associate with endogenous lipoprotein trafficking pathways and this, in addition to albumin binding, controls their plasma pharmacokinetics. We find that conjugation to dialkyl lipids and cholesterol leads to higher association with lipid trafficking pathways, and more sustained plasma exposure, compared to conjugation to short and monoalkyl lipids. Our lipidated polymers can thus be utilised as delivery platforms to tune the plasma half-life of various pharmaceuticals.
Collapse
Affiliation(s)
- Mohammad Abdallah
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Lihuan Lin
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Ian K Styles
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Alexander Mörsdorf
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - James L Grace
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Gracia Gracia
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Cameron Nowell
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| | - John F Quinn
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia; Department of Chemical and Biological Engineering, Faculty of Engineering, Monash University, Clayton, VIC, Australia
| | - Cornelia B Landersdorfer
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Michael R Whittaker
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
| | - Natalie L Trevaskis
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
| |
Collapse
|
7
|
Kaminskas LM, Butcher NJ, Subasic CN, Kothapalli A, Haque S, Grace JL, Morsdorf A, Blanchfield JT, Whittaker AK, Quinn JF, Whittaker MR. Lipidated brush-PEG polymers as low molecular weight pulmonary drug delivery platforms. Expert Opin Drug Deliv 2024; 21:151-167. [PMID: 38248870 DOI: 10.1080/17425247.2024.2305116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2023] [Accepted: 01/03/2024] [Indexed: 01/23/2024]
Abstract
OBJECTIVES Nanomedicines are being actively developed as inhalable drug delivery systems. However, there is a distinct utility in developing smaller polymeric systems that can bind albumin in the lungs. We therefore examined the pulmonary pharmacokinetic behavior of a series of lipidated brush-PEG (5 kDa) polymers conjugated to 1C2, 1C12 lipid or 2C12 lipids. METHODS The pulmonary pharmacokinetics, patterns of lung clearance and safety of polymers were examined in rats. Permeability through monolayers of primary human alveolar epithelia, small airway epithelia and lung microvascular endothelium were also investigated, along with lung mucus penetration and cell uptake. RESULTS Polymers showed similar pulmonary pharmacokinetic behavior and patterns of lung clearance, irrespective of lipid molecular weight and albumin binding capacity, with up to 30% of the dose absorbed from the lungs over 24 h. 1C12-PEG showed the greatest safety in the lungs. Based on its larger size, 2C12-PEG also showed the lowest mucus and cell membrane permeability of the three polymers. While albumin had no significant effect on membrane transport, the cell uptake of C12-conjugated PEGs were increased in alveolar epithelial cells. CONCLUSION Lipidated brush-PEG polymers composed of 1C12 lipid may provide a useful and novel alternative to large nanomaterials as inhalable drug delivery systems.
Collapse
Affiliation(s)
- Lisa M Kaminskas
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| | - Neville J Butcher
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| | | | - Ashok Kothapalli
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| | - Shadabul Haque
- Drug Delivery Disposition Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| | - James L Grace
- Drug Delivery Disposition Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| | - Alexander Morsdorf
- Drug Delivery Disposition Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| | - Joanne T Blanchfield
- School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD, Australia
| | - Andrew K Whittaker
- Australian Institute of Bioengineering and Nanotechnology, University of Queensland, St Lucia, QLD, Australia
- Australian Research Council Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide, University of Queensland, St Lucia, QLD, Australia
| | - John F Quinn
- Drug Delivery Disposition Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
- Department of Chemical Engineering, Faculty of Engineering, Monash University, Clayton, VIC, Australia
| | - Michael R Whittaker
- Drug Delivery Disposition Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| |
Collapse
|
8
|
Ibrahim JP, Butcher NJ, Kothapalli A, Subasic CN, Blanchfield JT, Whittaker AK, Whittaker MR, Kaminskas LM. Utilization of endogenous albumin trafficking pathways in the lungs has potential to modestly increase the lung interstitial access and absorption of drug delivery systems after inhaled administration. Expert Opin Drug Deliv 2023; 20:1145-1155. [PMID: 37535434 DOI: 10.1080/17425247.2023.2244881] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2023] [Revised: 07/25/2023] [Accepted: 07/26/2023] [Indexed: 08/05/2023]
Abstract
OBJECTIVES Drug delivery systems typically show limited access to the lung interstitium and absorption after pulmonary delivery. The aim of this work was to undertake a proof-of-concept investigation into the potential of employing endogenous albumin and albumin absorption mechanisms in the lungs to improve lung interstitial access and absorption of inhaled drug delivery systems that bind albumin. METHODS The permeability of human albumin (HSA) through monolayers of primary human alveolar epithelia, small airway epithelia, and microvascular endothelium were investigated. The pulmonary pharmacokinetics of bovine serum albumin (BSA) was also investigated in efferent caudal mediastinal lymph duct-cannulated sheep after inhaled aerosol administration. RESULTS Membrane permeability coefficient values (Papp) of HSA increased in the order alveolar epithelia CONCLUSION Drug delivery systems that bind endogenous albumin may show a modest increase in lung permeability and absorption after inhaled delivery compared to systems that do not efficiently bind albumin.
Collapse
Affiliation(s)
- Jibriil P Ibrahim
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| | - Neville J Butcher
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| | - Ashok Kothapalli
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| | | | - Joanne T Blanchfield
- School of Chemistry and Molecular Biosciences, University of Queensland, St Lucia, QLD, Australia
| | - Andrew K Whittaker
- Australian Institute of Bioengineering and Nanotechnology, University of Queensland, St Lucia, QLD, Australia
- Australian Research Council Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide, University of Queensland, St Lucia, QLD, Australia
| | - Michael R Whittaker
- Drug Delivery Disposition Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| | - Lisa M Kaminskas
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| |
Collapse
|
9
|
Khaw KY, Whittaker MR, Kuruppu S, Chan KG, Gan SH, Goh BH. Editorial: The inaugural Monash international health science and technology conference: pharmacology perspectives. Front Pharmacol 2023; 14:1208546. [PMID: 37229254 PMCID: PMC10203568 DOI: 10.3389/fphar.2023.1208546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2023] [Accepted: 05/02/2023] [Indexed: 05/27/2023] Open
Affiliation(s)
- Kooi Yeong Khaw
- School of Pharmacy, Monash University Malaysia, Selangor, Malaysia
| | - Michael R. Whittaker
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Sanjaya Kuruppu
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia
| | - Kok Gan Chan
- Division of Genetics and Molecular Biology, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia
- International Genome Centre, Jiangsu University, Zhenjiang, China
| | - Siew Hua Gan
- School of Pharmacy, Monash University Malaysia, Selangor, Malaysia
| | - Bey Hing Goh
- School of Pharmacy, Monash University Malaysia, Selangor, Malaysia
- College of Pharmaceutical Sciences, Zhejiang University, Zhejiang, China
- Biofunctional Molecule Exploratory (BMEX) Research Group, School of Pharmacy, Monash University Malaysia, Selangor, Malaysia
| |
Collapse
|
10
|
Ercole F, Kim CJ, Dao NV, Tse WKL, Whittaker MR, Caruso F, Quinn JF. Synthesis of Thermoresponsive, Catechol-Rich Poly(ethylene glycol) Brush Polymers for Attenuating Cellular Oxidative Stress. Biomacromolecules 2023; 24:387-399. [PMID: 36469858 DOI: 10.1021/acs.biomac.2c01211] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Herein, we report a platform to integrate customizable quantities of catechol units into polymers by reacting caffeic acid carbonic anhydride with polymers having pendant amine groups. Brush poly(ethylene glycol)-caffeamide (PEG-CAF) copolymers based on oligo(ethylene glycol)methyl ether methacrylate (OEGMA500) were obtained with a catechol content of approximately 30, 40, and 50 mol % (vs OEGMA content). Owing to the hydrophobicity of the introduced CAF groups, the catechol copolymers exhibited cloud points in the range of 23-46 °C and were used to fabricate thermoresponsive FeIII metal-phenolic network capsules. Polymers with the highest CAF content (50 mol %) proved most effective for attenuating reactive oxygen species levels in vitro, in co-cultured fibroblasts, and breast cancer cells, even in the presence of an exogenous oxidant source. The reported approach to synthesize customizable catechol materials could be generalized to other amine-functional polymers, with potential biomedical applications such as adhesives or stimuli-responsive drug delivery systems.
Collapse
Affiliation(s)
- Francesca Ercole
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Chan-Jin Kim
- Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia
| | - Nam V Dao
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.,Department of Physical Chemistry and Physics, Hanoi University of Pharmacy, Hanoi 10000, Vietnam
| | - Warren K L Tse
- Department of Chemical Engineering, Faculty of Engineering, Monash University, Clayton, Victoria 3800, Australia
| | - Michael R Whittaker
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Frank Caruso
- Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia
| | - John F Quinn
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.,Department of Chemical Engineering, Faculty of Engineering, Monash University, Clayton, Victoria 3800, Australia
| |
Collapse
|
11
|
Wyers D, Quinn JF, Whittaker MR, Greening C, Jirapanjawat T, Junkers T. Narrowing Down Chain Length Effects on the Antibacterial Action of Guanylated Oligomers. Polym Chem 2023. [DOI: 10.1039/d3py00203a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023]
Abstract
Synthesis of monodisperse guanylated oligomers through reversible addition fragmentation chain transfer (RAFT) polymerization of 2-boc aminoethyl acrylate followed by flash chromatography is described. To achieve antimicrobial action, the RAFT-derived protected...
Collapse
|
12
|
Ibrahim JP, Haque S, Bischof RJ, Whittaker AK, Whittaker MR, Kaminskas LM. Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep. Front Pharmacol 2022; 13:880448. [PMID: 35721215 PMCID: PMC9201389 DOI: 10.3389/fphar.2022.880448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2022] [Accepted: 04/22/2022] [Indexed: 12/03/2022] Open
Abstract
Enhancing the delivery of therapeutic agents to the lung lymph, including drugs, transfection agents, vaccine antigens and vectors, has the potential to significantly improve the treatment and prevention of a range of lung-related illnesses. One way in which lymphatic delivery can be optimized is via the use of nanomaterial-based carriers, such as liposomes. After inhaled delivery however, there is conflicting information in the literature regarding whether nanomaterials can sufficiently access the lung lymphatics to have a therapeutic benefit, in large part due to a lack of reliable quantitative pharmacokinetic data. The aim of this work was to quantitatively evaluate the pulmonary lymphatic pharmacokinetics of a model nanomaterial-based drug delivery system (HSPC liposomes) in caudal mediastinal lymph duct cannulated sheep after nebulized administration to the lungs. Liposomes were labelled with 3H-phosphatidylcholine to facilitate evaluation of pharmacokinetics and biodistribution in biological samples. While nanomaterials administered to the lungs may access the lymphatics via direct absorption from the airways or after initial uptake by alveolar macrophages, only 0.3 and 0.001% of the 3H-lipid dose was recovered in lung lymph fluid and lymph cell pellets (containing immune cells) respectively over 5 days. This suggests limited lymphatic access of liposomes, despite apparent pulmonary bioavailability of the 3H-lipid being approximately 17%, likely a result of absorption of liberated 3H-lipid after breakdown of the liposome in the presence of lung surfactant. Similarly, biodistribution of 3H in the mediastinal lymph node was insignificant after 5 days. These data suggest that liposomes, that are normally absorbed via the lymphatics after interstitial administration, do not access the lung lymphatics after inhaled administration. Alternate approaches to maximize the lung lymphatic delivery of drugs and other therapeutics need to be identified.
Collapse
Affiliation(s)
- Jibriil P Ibrahim
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| | - Shadabul Haque
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Robert J Bischof
- School of Science, Psychology and Sport, Federation University, Berwick, VIC, Australia
| | - Andrew K Whittaker
- Australian Institute for Bioengineering and Nanotechnology, School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD, Australia
| | - Michael R Whittaker
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Lisa M Kaminskas
- School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia
| |
Collapse
|
13
|
Urquhart MC, Ercole F, Clulow AJ, Davis TP, Whittaker MR, Boyd BJ, Quinn JF. Thiol-responsive lyotropic liquid crystals exhibit triggered phase re-arrangement and hydrogen sulfide (H 2S) release. J Colloid Interface Sci 2022; 613:218-223. [PMID: 35033767 DOI: 10.1016/j.jcis.2021.12.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2021] [Revised: 12/27/2021] [Accepted: 12/28/2021] [Indexed: 10/19/2022]
Abstract
Hydrogen sulfide (H2S) is an important signalling molecule with potential pharmaceutical applications. In pursuit of a suitable delivery system for H2S, herein we apply an amphiphilic trisulfide to concomitantly alter the mesophase behaviour of dispersed lipid particles and enable triggered H2S release. Amperometric release studies indicate the trisulfide acts as a sustained H2S donor, with inclusion into the mesophase attenuating release vs neat dispersed trisulfide. Taken together the results highlight the potential for including trisulfide-based additives in stimuli-responsive drug delivery vehicles.
Collapse
Affiliation(s)
- Matthew C Urquhart
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Francesca Ercole
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Andrew J Clulow
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia; BioSAXS beamline, Australian Synchrotron, ANSTO, 800 Blackburn Road, Clayton, Victoria 3168, Australia
| | - Thomas P Davis
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia; Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Michael R Whittaker
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Ben J Boyd
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia; Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen 2100, Denmark.
| | - John F Quinn
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia; Department of Chemical Engineering, Faculty of Engineering, Monash University, Parkville, Victoria 3052, Australia.
| |
Collapse
|
14
|
Dao NV, Ercole F, Li Y, Davis TP, Kaminskas LM, Sloan EK, Quinn JF, Whittaker MR. Nitroxide-functional PEGylated nanostars arrest cellular oxidative stress and exhibit preferential accumulation in co-cultured breast cancer cells. J Mater Chem B 2021; 9:7805-7820. [PMID: 34586131 DOI: 10.1039/d1tb00812a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The limited application of traditional antioxidants to reducing elevated levels of reactive oxygen species (ROS) is potentially due to their lack of stability and biocompatibility when tested in a biological milieu. For instance, the poor biological antioxidant performance of small molecular nitroxides arises from their limited diffusion across cell membranes and their significant side effects when applied at high doses. Herein, we describe the use of nanostructured carriers to improve the antioxidant activity of a typical nitroxide derivative, (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO). Polymers with star-shaped structures were synthesised and were further conjugated to TEMPO moieties via amide linkages. The TEMPO-loaded stars have small hydrodynamic sizes (<20 nm), and are better tolerated by cells than free TEMPO in a breast cancer-fibroblast co-culture, a system exhibiting elevated ROS levels. At a well-tolerated concentration, the polymer with the highest TEMPO-loading capacity successfully downregulated ROS production in co-cultured cells (a significant decrease of up to 50% vs. basal ROS levels), which was accompanied by a specific reduction in superoxide anion generation in the mitochondria. In contrast, the equivalent concentration of free TEMPO did not achieve the same outcome. Further investigation showed that the TEMPO-conjugated star polymers can be recycled inside the cells, thus providing longer term scavenging activity. Cell association studies demonstrated that the polymers can be taken up by both cell types in the co-culture, and are found to co-locate with the mitochondria. Interestingly the stars exhibited preferential mitochodria targeting in the co-cultured cancer cells compared to accompanying fibroblasts. The data suggest the potential of TEMPO-conjugated star polymers to arrest oxidative stress for various applications in cancer therapy.
Collapse
Affiliation(s)
- Nam V Dao
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. .,Department of Physical Chemistry and Physics, Hanoi University of Pharmacy, Hanoi 10000, Vietnam
| | - Francesca Ercole
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| | - Yuhuan Li
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. .,Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Fudan University, Shanghai 200032, China
| | - Thomas P Davis
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. .,Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Lisa M Kaminskas
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Erica K Sloan
- Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.,Peter MacCallum Cancer Centre, Division of Surgery, Melbournem, VIC 3000, Australia
| | - John F Quinn
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. .,Department of Chemical Engineering, Faculty of Engineering, Monash University, Wellington Road, Clayton, Victoria 3800, Australia
| | - Michael R Whittaker
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| |
Collapse
|
15
|
Stadler B, Nowell CJ, Whittaker MR, Arnhold S, Pilatz A, Wagenlehner FM, Exintaris B, Middendorff R. Physiological and pharmacological impact of oxytocin on epididymal propulsion during the ejaculatory process in rodents and men. FASEB J 2021; 35:e21639. [PMID: 34041782 DOI: 10.1096/fj.202100435r] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/09/2021] [Accepted: 04/15/2021] [Indexed: 01/12/2023]
Abstract
During the emission phase of ejaculation, the sperm is driven from the cauda epididymidis, where it is stored, through the vas deferens by strong contractions. These contractions are thought of as being mainly induced by the sympathetic nervous system and the neurotransmitter noradrenaline. In the present study, we investigated the effect of oxytocin (suggested to exert effects during ejaculation as well) on defined segments of the rat and human epididymis using live imaging. Our results indicate that it is the very last part of the epididymis, segment 19 (S19) in rat and likewise segment 9 in human, which responds in a uniquely strong and rapid manner to oxytocin (similar to noradrenaline). Because of the complex nature of this contractile response, we developed an imaging analysis method, which allowed us to quantify multidirectional contractions and to display them using heat maps. The reaction of S19 to oxytocin was concentration-dependent and could be inhibited by pretreatment with oxytocin antagonists (atosiban and cligosiban), but not with an arginine vasopressin 1A antagonist (SR49059). In both rat and human tissue, pretreatment with the alpha-1 adrenoreceptor antagonist tamsulosin inhibited the response to noradrenaline, whereas the effect of oxytocin was unimpaired. Our data (from men and rodents) strongly suggest that the hormone oxytocin is involved in the ejaculatory process. Thus, oxytocin-based medications might be a promising non-adrenergic treatment option for ejaculatory disorders. Additionally, we propose that S19 could be an advantageous model (detecting very low concentrations of oxytocin) to test the bioactivity of new oxytocin agonists and oxytocin antagonists.
Collapse
Affiliation(s)
- Beatrix Stadler
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany.,Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia
| | - Cameron J Nowell
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia
| | - Michael R Whittaker
- Drug Discovery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia
| | - Stefan Arnhold
- Institute of Veterinary Anatomy Histology and Embryology, Justus-Liebig-University, Giessen, Germany
| | - Adrian Pilatz
- Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig-University, Giessen, Germany
| | - Florian M Wagenlehner
- Department of Urology, Pediatric Urology, and Andrology, Justus-Liebig-University, Giessen, Germany
| | - Betty Exintaris
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia
| | - Ralf Middendorff
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| |
Collapse
|
16
|
Albayaty YN, Thomas N, Ramírez-García PD, Davis TP, Quinn JF, Whittaker MR, Prestidge CA. Polymeric micelles with anti-virulence activity against Candida albicans in a single- and dual-species biofilm. Drug Deliv Transl Res 2021; 11:1586-1597. [PMID: 33713317 DOI: 10.1007/s13346-021-00943-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/08/2021] [Indexed: 12/15/2022]
Abstract
Infections caused by fungal biofilms with rapidly evolving resistance against the available antifungal agents are difficult to manage. These difficulties demand new strategies for effective eradication of biofilms from both biological and inert surfaces. In this study, polymeric micelles comprised of di-block polymer, poly-(ethylene glycol) methyl ether methacrylate and poly 2-(N,N-diethylamino) ethyl methacrylate polymer, P(PEGMA-b-DEAEMA), were observed to exhibit remarkable inhibitory effects on hyphal growth of Candida albicans (C. albicans) and C. tropicalis, thus preventing biofilm formation and removing existing biofilms. P(PEGMA-b-DEAEMA) micelles showed biofilm removal efficacy of > 40% and a 1.4-log reduction in cell viability of C. albicans in its single-species biofilms. In addition, micelles alone promoted high removal percentage in a mixed biofilm of C. albicans and C. tropicalis (~ 70%) and remarkably reduced cell viability of both strains. Co-delivery of fluconazole (Flu) and amphotericin B (AmB) with micelles showed synergistic effects on C. albicans biofilms (3-log reduction for AmB and 2.2-log reduction for Flu). Similar effects were noted on C. albicans planktonic cells when treated with the micellar system combined with AmB but not with Flu. Moreover, micelle-drug combinations showed an enhancement in the antibiofilm activity of Flu and AmB against dual-species biofilms. Furthermore, in vivo studies using Caenorhabditis elegans nematodes revealed no obvious toxicity of the micelles. Targeting morphologic transitions provides a new strategy for defeating fungal biofilms of polymorphic resistance strains and can be potentially used in counteracting Candida virulence.
Collapse
Affiliation(s)
- Yassamin N Albayaty
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia
- Basil Hetzel Institute for Translational Health Research, Woodville South, Woodville, SA, 5011, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, Australia
| | - Nicky Thomas
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia
- Basil Hetzel Institute for Translational Health Research, Woodville South, Woodville, SA, 5011, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, Australia
| | - Paulina D Ramírez-García
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, Australia
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC, 3052, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, Australia
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC, 3052, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, Australia
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC, 3052, Australia
- Department of Chemical Engineering, Faculty of Engineering, Monash University, Wellington Road, Clayton, VIC, 3800, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, Australia
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC, 3052, Australia
| | - Clive A Prestidge
- UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA, 5000, Australia.
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Parkville, Australia.
| |
Collapse
|
17
|
Albayaty YN, Thomas N, Ramírez-García PD, Davis TP, Quinn JF, Whittaker MR, Prestidge CA. pH-Responsive copolymer micelles to enhance itraconazole efficacy against Candida albicans biofilms. J Mater Chem B 2021; 8:1672-1681. [PMID: 32016213 DOI: 10.1039/c9tb02586c] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Candida albicans (C. albicans) is a common fungal pathogen causing both localised and systemic infections. The majority of these infections are promoted by biofilm formation, providing a protective matrix for the embedded fungi thereby evading the host immune defence and promoting resistance against anti-mycotic agents. In this study, pH-responsive micellar systems based on poly-(ethylene glycol) ethyl ether methacrylate (PEGMA) and poly 2-(diethylamino) ethyl methacrylate (DEAEMA) block-copolymers of P(PEGMA-b-DEAEMA) were specifically developed and loaded with the antifungal itraconazole (ICZ) to defeat C. albicans biofilms. The P(PEGMA-b-DEAEMA) di-block polymer micelles demonstrated a particle size of 55 ± 6 nm and high ICZ loads (12.0 ± 0.5% w/w). Within the biofilm's acidic microenvironment, tertiary amines of the pH-sensitive DEAEMA block are protonated, altering their conformation and enhancing the release of the micellar contents. Encapsulation of ICZ within micelles significantly enhanced the activity against C. albicans biofilms, with a significant reduction in the biofilm biomass (>50%) and in the number of viable cells (2.4 Log reduction) achieved, compared with the non-encapsulated ICZ. Confocal microscopy revealed a high affinity and accumulation of the micelles in C. albicans biofilms as a result of their size and specific electrostatic interaction, hence their improved activity. P(PEGMA-b-DEAEMA) based pH-responsive micelles offer significant potential as antifungal carriers for controlling Candida infections.
Collapse
Affiliation(s)
- Yassamin N Albayaty
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia. and Basil Hetzel Institute for Translational Health Research, Woodville South, 5011, South Australia, Australia and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia
| | - Nicky Thomas
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia. and Basil Hetzel Institute for Translational Health Research, Woodville South, 5011, South Australia, Australia and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia
| | - Paulina D Ramírez-García
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia and Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia and Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia and Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia and Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Clive A Prestidge
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA, Australia. and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Australia
| |
Collapse
|
18
|
Dao NV, Ercole F, Urquhart MC, Kaminskas LM, Nowell CJ, Davis TP, Sloan EK, Whittaker MR, Quinn JF. Trisulfide linked cholesteryl PEG conjugate attenuates intracellular ROS and collagen-1 production in a breast cancer co-culture model. Biomater Sci 2021; 9:835-846. [PMID: 33231231 DOI: 10.1039/d0bm01544j] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The progression of cancer has been closely-linked with augmentation of cellular reactive oxygen species (ROS) levels and ROS-associated changes in the tumour microenvironment (TME), including alterations to the extracellular matrix and associated low drug uptake. Herein we report the application of a co-culture model to simulate the ROS based cell-cell interactions in the TME using fibroblasts and breast cancer cells, and describe how novel reactive polymers can be used to modulate those interactions. Under the co-culture conditions, both cell types exhibited modifications in behaviour, including significant overproduction of ROS in the cancer cells, and elevation of the collagen-1 secretion and stained actin filament intensity in the fibroblasts. To examine the potential of using reactive antioxidant polymers to intercept ROS communication and thereby manipulate the TME, we employed H2S-releasing macromolecular conjugates which have been previously demonstrated to mitigate ROS production in HEK cells. The specific conjugate used, mPEG-SSS-cholesteryl (T), significantly reduced ROS levels in co-cultured cancer cells by approximately 50%. This reduction was significantly greater than that observed with the other positive antioxidant controls. Exposure to T was also found to downregulate levels of collagen-1 in the co-cultured fibroblasts, while exhibiting less impact on cells in mono-culture. This would suggest a possible downstream effect of ROS-mitigation by T on stromal-tumour cell signalling. Since fibroblast-derived collagens modulate crucial steps in tumorigenesis, this ROS-associated effect could potentially be harnessed to slow cancer progression. The model may also be beneficial for interrogating the impact of antioxidants on naturally enhanced ROS levels, rather than relying on the application of exogenous oxidants to simulate elevated ROS levels.
Collapse
Affiliation(s)
- Nam V Dao
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. and Department of Physical Chemistry and Physics, Hanoi University of Pharmacy, Hanoi 10000, Vietnam
| | - Francesca Ercole
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| | - Matthew C Urquhart
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| | - Lisa M Kaminskas
- School of Biomedical Sciences, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Cameron J Nowell
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
| | - Thomas P Davis
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Erica K Sloan
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia and Peter MacCallum Cancer Centre, Division of Surgery, Melbourne, VIC 3000, Australia
| | - Michael R Whittaker
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| | - John F Quinn
- Australian Research Council - Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. and Department of Chemical Engineering, Faculty of Engineering, Monash University, Wellington Road, Clayton, Victoria 3800, Australia
| |
Collapse
|
19
|
Dao NV, Ercole F, Kaminskas LM, Davis TP, Sloan EK, Whittaker MR, Quinn JF. Trisulfide-Bearing PEG Brush Polymers Donate Hydrogen Sulfide and Ameliorate Cellular Oxidative Stress. Biomacromolecules 2020; 21:5292-5305. [PMID: 33210534 DOI: 10.1021/acs.biomac.0c01347] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A potential approach to combat cellular dysfunction is to manipulate cell communication and signaling pathways to restore physiological functions while protecting unaffected cells. For instance, delivering the signaling molecule H2S to certain cells has been shown to restore cell viability and re-normalize cell behavior. We have previously demonstrated the ability to incorporate a trisulfide-based H2S-donating moiety into linear polymers with good in vitro releasing profiles and demonstrated their potential for ameliorating oxidative stress. Herein, we report two novel series of brush polymers decorated with higher numbers of H2S-releasing segments. These materials contain two trisulfide-based monomers co-polymerized with oligo(ethylene glycol methyl ether methacrylate) via reversible addition-fragmentation chain-transfer polymerization. The macromolecules were characterized to have a range of trisulfide densities with similar, well-defined molecular weight distribution, good H2S-releasing profiles, and high cellular tolerance. Using an amperometric technique, the H2S liberated and total sulfide release were found to depend on concentrations and chemical nature of triggering molecules (glutathione and cysteine) and, importantly, the position of reactive groups within the brush structure. Notably, when introduced to cells at well-tolerated doses, two macromolecular donors which have the same proportion as of the H2S-donating monomer (30%) but differ in releasing moiety location show similar cellular H2S-releasing kinetics. These donors can restore reactive oxygen species levels to baseline values, when polymer pretreated cells are exposed to exogenous oxidants (H2O2). Our work opens up a new aspect in preparing H2S macromolecule donors and their application to arresting cellular oxidative cascades.
Collapse
Affiliation(s)
- Nam V Dao
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology; Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.,Department of Physical Chemistry and Physics, Hanoi University of Pharmacy, Hanoi 10000, Vietnam
| | - Francesca Ercole
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology; Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Lisa M Kaminskas
- School of Biomedical Sciences, University of Queensland, St Lucia, Queensland 4072, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology; Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.,Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland 4072, Australia
| | - Erica K Sloan
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.,Division of Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology; Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology; Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.,Department of Chemical Engineering, Faculty of Engineering, Monash University, Wellington Road, Clayton, Victoria 3800, Australia
| |
Collapse
|
20
|
Stadler B, Whittaker MR, Exintaris B, Middendorff R. Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists. Front Endocrinol (Lausanne) 2020; 11:565731. [PMID: 33193084 PMCID: PMC7642622 DOI: 10.3389/fendo.2020.565731] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 09/07/2020] [Indexed: 12/12/2022] Open
Abstract
In this review, the role of oxytocin and oxytocin-like agents (acting via the oxytocin receptor and belonging to the oxytocin-family) in the male reproductive tract is considered. Previous research (dating back over 60 years) is revised and connected with recently found aspects of the role oxytocin plays in male reproductive health. The local expression of oxytocin and its receptor in the male reproductive tract of different species is summarized. Colocalization and possible crosstalk to other agents and receptors and their resulting effects are discussed. The role of the newly reported oxytocin focused signaling pathways in the male reproductive tract, other than mediating contractility, is critically examined. The structure and effect of the most promising oxytocin-agonists and -antagonists are reviewed for their potential in treating male disorders with origins in the male reproductive tract such as prostate diseases and ejaculatory disorders.
Collapse
Affiliation(s)
- Beatrix Stadler
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| | - Michael R. Whittaker
- Drug Discovery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia
| | - Betty Exintaris
- Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Melbourne, VIC, Australia
| | - Ralf Middendorff
- Institute of Anatomy and Cell Biology, Justus-Liebig-University, Giessen, Germany
| |
Collapse
|
21
|
Haque S, Pouton CW, McIntosh MP, Ascher DB, Keizer DW, Whittaker MR, Kaminskas LM. The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats. Nanomedicine 2020; 30:102291. [PMID: 32841737 DOI: 10.1016/j.nano.2020.102291] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/28/2020] [Revised: 08/05/2020] [Accepted: 08/12/2020] [Indexed: 11/16/2022]
Abstract
Polylactide-co-glycolide (PLGA) nanoparticles are one of the most commonly explored biodegradable polymeric drug carriers for inhaled delivery. Despite their advantages as inhalable nanomedicine scaffolds, we still lack a complete understanding of the kinetics and major pathways by which these materials are cleared from the lungs. This information is important to evaluate their safety over prolonged use and enable successful clinical translation. This study aimed to determine how the size and charge of 3H-labeled PLGA nanoparticles affect the kinetics and mechanisms by which they are cleared from the lungs and their safety in the lungs. The results showed that lung clearance kinetics and retention patterns were more significantly defined by particle size, whereas lung clearance pathways were largely influenced by particle charge. Each of the nanoparticles caused transient inflammatory changes in the lungs after a single dose that reflected lung retention times.
Collapse
Affiliation(s)
- Shadabul Haque
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Melbourne, VIC, Australia
| | - Colin W Pouton
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| | - Michelle P McIntosh
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
| | - David B Ascher
- Bio21 Institute, University of Melbourne, Melbourne, VIC, Australia
| | - David W Keizer
- Bio21 Institute, University of Melbourne, Melbourne, VIC, Australia
| | - Michael R Whittaker
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Melbourne, VIC, Australia.
| | - Lisa M Kaminskas
- Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia; School of Biomedical Sciences, University of Queensland, St Lucia, QLD, Australia.
| |
Collapse
|
22
|
Abdallah M, Müllertz OO, Styles IK, Mörsdorf A, Quinn JF, Whittaker MR, Trevaskis NL. Lymphatic targeting by albumin-hitchhiking: Applications and optimisation. J Control Release 2020; 327:117-128. [PMID: 32771478 DOI: 10.1016/j.jconrel.2020.07.046] [Citation(s) in RCA: 48] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 07/27/2020] [Accepted: 07/29/2020] [Indexed: 12/20/2022]
Abstract
The lymphatic system plays an integral role in the development and progression of a range of disease conditions, which has impelled medical researchers and clinicians to design, develop and utilize advanced lymphatic drug delivery systems. Following interstitial administration, most therapeutics and molecules are cleared from tissues via the draining blood capillaries. Macromolecules and delivery systems >20 kDa in size or 10-100 nm in diameter are, however, transported from the interstitium via draining lymphatic vessels as they are too large to cross the blood capillary endothelium. Lymphatic uptake of small molecules can be promoted by two general approaches: administration in association with synthetic macromolecular constructs, or through hitchhiking on endogenous cells or macromolecular carriers that are transported from tissues via the lymphatics. In this paper we review the latter approach where molecules are targeted to lymph by hitchhiking on endogenous albumin transport pathways after subcutaneous, intramuscular or intradermal injection. We describe the properties of the lymphatic system and albumin that are relevant to lymphatic targeting, the characteristics of drugs and delivery systems designed to hitchhike on albumin trafficking pathways and how to further optimise these properties, and finally the current applications and potential future directions for albumin-hitchhiking approaches to target the lymphatics.
Collapse
Affiliation(s)
- Mohammad Abdallah
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
| | - Olivia O Müllertz
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Australia; Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Ian K Styles
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Australia
| | - Alexander Mörsdorf
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
| | - John F Quinn
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
| | - Michael R Whittaker
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia
| | - Natalie L Trevaskis
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Australia.
| |
Collapse
|
23
|
Qiao R, Fu C, Li Y, Qi X, Ni D, Nandakumar A, Siddiqui G, Wang H, Zhang Z, Wu T, Zhong J, Tang S, Pan S, Zhang C, Whittaker MR, Engle JW, Creek DJ, Caruso F, Ke PC, Cai W, Whittaker AK, Davis TP. Sulfoxide-Containing Polymer-Coated Nanoparticles Demonstrate Minimal Protein Fouling and Improved Blood Circulation. Adv Sci (Weinh) 2020; 7:2000406. [PMID: 32670765 PMCID: PMC7341081 DOI: 10.1002/advs.202000406] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 03/19/2020] [Indexed: 05/15/2023]
Abstract
Minimizing the interaction of nanomedicines with the mononuclear phagocytic system (MPS) is a critical challenge for their clinical translation. Conjugating polyethylene glycol (PEG) to nanomedicines is regarded as an effective approach to reducing the sequestration of nanomedicines by the MPS. However, recent concerns about the immunogenicity of PEG highlight the demand of alternative low-fouling polymers as innovative coating materials for nanoparticles. Herein, a highly hydrophilic sulfoxide-containing polymer-poly(2-(methylsulfinyl)ethyl acrylate) (PMSEA)-is used for the surface coating of iron oxide nanoparticles (IONPs). It is found that the PMSEA polymer coated IONPs have a more hydrophilic surface than their PEGylated counterparts, and demonstrate remarkably reduced macrophage cellular uptake and much less association with human plasma proteins. In vivo study of biodistribution and pharmacokinetics further reveals a much-extended blood circulation (≈2.5 times longer in terms of elimination half-life t 1/2) and reduced accumulation (approximately two times less) in the organs such as the liver and spleen for IONPs coated by PMSEA than those by PEG. It is envisaged that the highly hydrophilic sulfoxide-containing polymers have huge potential to be employed as an advantageous alternative to PEG for the surface functionalization of a variety of nanoparticles for long circulation and improved delivery.
Collapse
Affiliation(s)
- Ruirui Qiao
- ARC Centre of Excellence in Convergent Bio‐Nano Science and Technology and Australian Institute for Bioengineering and NanotechnologyThe University of QueenslandBrisbaneQLD4072Australia
- ARC Centre of Excellence in Convergent Bio‐Nano Science and TechnologyMonash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| | - Changkui Fu
- ARC Centre of Excellence in Convergent Bio‐Nano Science and Technology and Australian Institute for Bioengineering and NanotechnologyThe University of QueenslandBrisbaneQLD4072Australia
| | - Yuhuan Li
- ARC Centre of Excellence in Convergent Bio‐Nano Science and TechnologyMonash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| | - Xiaole Qi
- Key Laboratory of Modern Chinese MedicinesChina Pharmaceutical UniversityNanjing210009China
| | - Dalong Ni
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Aparna Nandakumar
- ARC Centre of Excellence in Convergent Bio‐Nano Science and TechnologyMonash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| | - Ghizal Siddiqui
- Monash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| | - Haiyan Wang
- Institute for HepatologyNational Clinical Research Center for Infectious DiseaseShenzhen Third People's HospitalGuangdong ProvinceShenzhen518112China
| | - Zheng Zhang
- Institute for HepatologyNational Clinical Research Center for Infectious DiseaseShenzhen Third People's HospitalGuangdong ProvinceShenzhen518112China
| | - Tingting Wu
- College of Food Science & TechnologyShanghai Ocean UniversityShanghai201306China
| | - Jian Zhong
- College of Food Science & TechnologyShanghai Ocean UniversityShanghai201306China
| | - Shi‐Yang Tang
- Department of ElectronicElectrical and Systems EngineeringSchool of EngineeringUniversity of BirminghamEdgbastonBirminghamB15 2TTUK
| | - Shuaijun Pan
- ARC Centre of Excellence in Convergent Bio‐Nano Science and Technologyand the Department of Chemical EngineeringThe University of MelbourneParkvilleVictoria3010Australia
| | - Cheng Zhang
- ARC Centre of Excellence in Convergent Bio‐Nano Science and Technology and Australian Institute for Bioengineering and NanotechnologyThe University of QueenslandBrisbaneQLD4072Australia
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio‐Nano Science and TechnologyMonash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| | - Jonathan W. Engle
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Darren J. Creek
- Monash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| | - Frank Caruso
- ARC Centre of Excellence in Convergent Bio‐Nano Science and Technologyand the Department of Chemical EngineeringThe University of MelbourneParkvilleVictoria3010Australia
| | - Pu Chun Ke
- ARC Centre of Excellence in Convergent Bio‐Nano Science and TechnologyMonash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| | - Weibo Cai
- Departments of Radiology and Medical PhysicsUniversity of Wisconsin – MadisonMadisonWI53705USA
| | - Andrew K. Whittaker
- ARC Centre of Excellence in Convergent Bio‐Nano Science and Technology and Australian Institute for Bioengineering and NanotechnologyThe University of QueenslandBrisbaneQLD4072Australia
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio‐Nano Science and Technology and Australian Institute for Bioengineering and NanotechnologyThe University of QueenslandBrisbaneQLD4072Australia
- ARC Centre of Excellence in Convergent Bio‐Nano Science and TechnologyMonash Institute of Pharmaceutical SciencesMonash University381 Royal ParadeParkvilleVIC3052Australia
| |
Collapse
|
24
|
Goos JACM, Davydova M, Lengkeek N, Greguric I, Whittaker MR, Quinn JF, Baell JB, Lewis JS, Davis TP. pH‐Responsive Polymers for Improving the Signal‐to‐Noise Ratio of Hypoxia PET Imaging with [
18
F]Fluoromisonidazole. Macromol Rapid Commun 2020. [DOI: 10.1002/marc.202070025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
25
|
Ercole F, Li Y, Whittaker MR, Davis TP, Quinn JF. H 2S-Donating trisulfide linkers confer unexpected biological behaviour to poly(ethylene glycol)-cholesteryl conjugates. J Mater Chem B 2020; 8:3896-3907. [PMID: 32227031 DOI: 10.1039/c9tb02614b] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Inspired by the properties of the naturally occurring H2S donor, diallyl trisulfide (DATS, extracted from garlic), the biological behaviour of trisulfide-bearing PEG-conjugates was explored. Specifically, three conjugates comprising an mPEG tail and a cholesteryl head were investigated: conjugates bridged by a trisulfide linker (T), a disulfide linker (D) or a carbamate linker (C), and a fourth comprising two mPEG tails bridged by a trisulfide linker (P). H2S testing using both a fluorescent chemical probe in HEK293 cells and an amperometric sensor to monitor release in suspended cells, demonstrated the ability of the trisulfide conjugates, T and P, to release H2S in the presence of cellular thiols. Cytotoxicity and cyto-protective capacity on HEK293 cells showed that T was the best tolerated of the conjugates studied, and remarkably more so than D or C. Moreover, it was noted that application of T conferred a protective effect to the cells, effectively abolishing the toxicity associated with co-administered C. The interaction of conjugates and combinations thereof with the cell membrane of HEK cells, as well as ROS generation were also investigated. It was found that C caused significant membrane perturbation, correlating with high losses in cell viability and pronounced generation of ROS, especially in the mitochondria. T, however, did not disturb the membrane and was able to mitigate the generation of ROS, especially in the mitochondria. The interplay of the cholesteryl group and H2S donation for conferring cytoprotective effects was clearly demonstrated as P did not display the same beneficial characteristics as T.
Collapse
Affiliation(s)
- Francesca Ercole
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| | | | | | | | | |
Collapse
|
26
|
Goos JACM, Davydova M, Dilling TR, Cho A, Cornejo MA, Gupta A, Price WS, Puttick S, Whittaker MR, Quinn JF, Davis TP, Lewis JS. Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue. Nucl Med Biol 2020; 84-85:63-72. [PMID: 32135473 PMCID: PMC7253331 DOI: 10.1016/j.nucmedbio.2020.02.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2019] [Revised: 02/07/2020] [Accepted: 02/24/2020] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Pretargeting strategies that do not rely on the expression of molecular targets have expanded imaging and therapy options for cancer patients. Nanostars with designed multivalency and which highly accumulate in tumor tissue via the enhanced permeability and retention (EPR) effect may therefore be the ideal vectors for the development of a passive pretargeting approach. METHODS Nanostars were synthesized, consisting of 7-8 center-cross-linked arms that were modified with trans-cyclooctene (TCO) using poly(ethylene glycol) (PEG) linkers of 12 or 106 monomer units or without linker. The bioorthogonal click reaction with radiofluorinated 2,2'-(7-(2-(tetrazine-poly(ethyleneglycol)11-amino)-2-oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid ([18F]F-Tz-PEG11-NODA) or 2,2'-(7-(2-(tetrazine-amino)-2-oxoethyl)-1,4,7-triazonane-1,4-diyl)diacetic acid ([18F]F-Tz-NODA) was measured by ex vivo biodistribution studies and positron emission tomography (PET) in mice bearing tumors with high EPR characteristics. Bioorthogonal masking was performed using a tetrazine-functionalized dextran polymer (Tz-DP). RESULTS Highest tumor accumulation of [18F]F-Tz-PEG11-NODA was observed for nanostars functionalized with TCO without linker, with a tumor uptake of 3.2 ± 0.4%ID/g and a tumor-to-muscle ratio of 12.8 ± 4.2, tumor-to-large intestine ratio of 0.5 ± 0.3 and tumor-to-kidney ratio of 2.0 ± 0.3, being significantly higher than for nanostars functionalized with TCO-PEG12 (P < 0.05) or TCO-PEG106 (P < 0.05). Tumor uptake and tumor-to-tissue ratios did not improve upon bioorthogonal masking with Tz-DP or when using a smaller, more lipophilic tetrazine([18F]F-Tz-NODA). CONCLUSIONS A pretargeting strategy was developed based on the passive delivery of TCO-functionalized nanostars. Such a strategy would allow for the imaging and treatment of tumors with apparent EPR characteristics, with high radioactive tumor doses and minimal doses to off-target tissues.
Collapse
Affiliation(s)
- Jeroen A C M Goos
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden; MedTechLabs, Stockholm, Sweden.
| | - Maria Davydova
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - Thomas R Dilling
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - Andrew Cho
- Department of Biochemistry & Structural Biology, Weill Cornell Graduate School, New York, USA; Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, USA
| | - Mike A Cornejo
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - Abhishek Gupta
- Nanoscale Organisation and Dynamics Group, Western Sydney University, Penrith, Australia
| | - William S Price
- Nanoscale Organisation and Dynamics Group, Western Sydney University, Penrith, Australia
| | - Simon Puttick
- Probing Biosystems Future Science Platform, Commonwealth Scientific and Industrial Research Organisation, Herston, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Australia
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, USA; Department of Radiology, the Molecular Pharmacology Program and the Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Radiology, Weill Cornell Medical College, New York, USA; Department Pharmacology, Weill Cornell Medical College, New York, USA
| |
Collapse
|
27
|
Urquhart MC, Dao NV, Ercole F, Boyd BJ, Davis TP, Whittaker MR, Quinn JF. Polymers with Dithiobenzoate End Groups Constitutively Release Hydrogen Sulfide upon Exposure to Cysteine and Homocysteine. ACS Macro Lett 2020; 9:553-557. [PMID: 35648511 DOI: 10.1021/acsmacrolett.0c00066] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Dithioesters are well-established as efficient reversible addition-fragmentation chain transfer (RAFT) agents. More recently, certain small molecule dithioesters have been reported to release the biological signaling molecule hydrogen sulfide (H2S) upon exposure to cysteine. Herein, we examine the propensity of polymers synthesized using RAFT with a dithioester chain transfer agent to release H2S via reaction of cysteine with constitutive dithioester end-groups. Homocysteine-triggered release of H2S from these materials is also observed, with evidence suggesting that the mechanism is analogous to the reaction with cysteine.
Collapse
Affiliation(s)
- Matthew C. Urquhart
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Nam V. Dao
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Francesca Ercole
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Ben J. Boyd
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
- Australian Institute for Bioengineering and Nanotechnology, University of Queensland, St Lucia, Queensland 4072, Australia
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - John F. Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, Victoria 3052, Australia
- Department of Chemical Engineering, Faculty of Engineering, Monash University, Wellington Road, Clayton, Victoria 3800, Australia
| |
Collapse
|
28
|
Goos JACM, Davydova M, Lengkeek N, Greguric I, Whittaker MR, Quinn JF, Baell JB, Lewis JS, Davis TP. pH-Responsive Polymers for Improving the Signal-to-Noise Ratio of Hypoxia PET Imaging with [ 18 F]Fluoromisonidazole. Macromol Rapid Commun 2020; 41:e2000061. [PMID: 32250004 DOI: 10.1002/marc.202000061] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 03/16/2020] [Accepted: 03/19/2020] [Indexed: 01/09/2023]
Abstract
To improve the signal-to-noise ratio of hypoxia positron emission tomography (PET) imaging, stimuli-responsive polymers are designed for the delivery of the hypoxia PET tracer fluorine-18 labeled fluoromisonidazole ([18 F]FMISO). Linear poly(N-(2-(hydroxypropyl)methacrylamide)) polymers are functionalized with hydrazide linkers that form pH-sensitive acyl hydrazone bonds after their conjugation to an [18 F]FMISO ketone analogue. The release of the [18 F]FMISO ketone analogue from the polymers is considerably faster at a lower pH and its uptake is significantly higher in cancer cells growing under acidic conditions. Additionally, the retention of the PET tracer is significantly higher in hypoxic cells compared to normoxic cells. The delivery of a PET tracer using stimuli-responsive polymers may be an attractive strategy to improve signal-to-noise ratios in PET imaging.
Collapse
Affiliation(s)
- Jeroen A C M Goos
- Department of Clinical Neuroscience and MedTechLabs, Karolinska Institute, Solna, 17177, Sweden
| | - Maria Davydova
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA
| | - Nigel Lengkeek
- Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW, 2234, Australia
| | - Ivan Greguric
- Australian Nuclear Science and Technology Organisation, Lucas Heights, NSW, 2234, Australia
| | - Michael R Whittaker
- Department of Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, 3052, Australia
| | - John F Quinn
- Department of Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, 3052, Australia
| | - Jonathan B Baell
- Department of Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, 3052, Australia
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA
| | - Thomas P Davis
- Department of Drug Delivery Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Parkville, VIC, 3052, Australia
| |
Collapse
|
29
|
Leiske MN, Mahmoud AM, Warne NM, Goos JACM, Pascual S, Montembault V, Fontaine L, Davis TP, Whittaker MR, Kempe K. Poly(2-isopropenyl-2-oxazoline) – a structural analogue to poly(vinyl azlactone) with Orthogonal Reactivity. Polym Chem 2020. [DOI: 10.1039/d0py00861c] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A modular copolymer platform based on two oxazole derivatives is presented. Post-polymerisation modifications revealed the potential to selectively modify the individual side groups, providing access to functional copolymer libraries in the future.
Collapse
|
30
|
Barbon SM, Truong NP, Elliott AG, Cooper MA, Davis TP, Whittaker MR, Hawker CJ, Anastasaki A. Elucidating the effect of sequence and degree of polymerization on antimicrobial properties for block copolymers. Polym Chem 2020. [DOI: 10.1039/c9py01435g] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Sequence-controlled copolymers have recently attracted great interest in a variety of applications, including antimicrobial materials.
Collapse
Affiliation(s)
- Stephanie M. Barbon
- Materials Research Laboratory
- University of California
- Santa Barbara
- Santa Barbara
- USA
| | - Nghia P. Truong
- Monash Institute of Pharmaceutical Sciences
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Monash University
- Parkville, Melbourne
- Australia
| | - Alysha G. Elliott
- Institute of Molecular Biosciences
- The University of Queensland
- Brisbane
- Australia
| | - Matthew A. Cooper
- Institute of Molecular Biosciences
- The University of Queensland
- Brisbane
- Australia
| | - Thomas P. Davis
- Monash Institute of Pharmaceutical Sciences
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Monash University
- Parkville, Melbourne
- Australia
| | - Michael R. Whittaker
- Monash Institute of Pharmaceutical Sciences
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Monash University
- Parkville, Melbourne
- Australia
| | - Craig J. Hawker
- Materials Research Laboratory
- University of California
- Santa Barbara
- Santa Barbara
- USA
| | - Athina Anastasaki
- Materials Research Laboratory
- University of California
- Santa Barbara
- Santa Barbara
- USA
| |
Collapse
|
31
|
Goos JA, Cho A, Carter LM, Dilling TR, Davydova M, Mandleywala K, Puttick S, Gupta A, Price WS, Quinn JF, Whittaker MR, Lewis JS, Davis TP. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect. Theranostics 2020; 10:567-584. [PMID: 31903138 PMCID: PMC6929988 DOI: 10.7150/thno.36777] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2019] [Accepted: 10/04/2019] [Indexed: 12/24/2022] Open
Abstract
Expression levels of biomarkers are generally unknown at initial diagnosis. The development of theranostic probes that do not rely on biomarker availability would expand therapy options for cancer patients, improve patient selection for nanomedicine and facilitate treatment of inoperable patients or patients with acquired therapy resistance. Herein, we report the development of star polymers, also known as nanostars, that allow for molecular imaging and/or endoradiotherapy based on passive targeting via the enhanced permeability and retention (EPR) effect. Methods: We synthesised a star copolymer, consisting of 7-8 centre-cross-linked arms that were modified with Gd3+ for magnetic resonance imaging (MRI), and functionalised either with 89Zr for in vivo quantification and positron emission tomography (PET) imaging, or with 177Lu for endoradiotherapy. 1H longitudinal relaxivities were determined over a continuum of magnetic field strengths ranging from 0.24 mT - 0.94 T at 37 °C (nuclear magnetic relaxation dispersion (NMRD) profile) and T 1-weighted MRI contrast enhancement was visualized at 3 T and 7 T. PET imaging and ex vivo biodistribution studies were performed in mice bearing tumours with high EPR (CT26) or low EPR (BxPC3) characteristics. Therapy studies were performed in mice with high EPR tumours and mean absorbed organ doses were estimated for a standard human model. Results: The star copolymer with Gd3+ displayed a significantly superior contrast enhancement ability (T 1 = 0.60 s) compared to the standard clinical contrast agent Gadovist (T 1 = 1.0 s). Quantification of tumour accumulation using the radiolabelled nanostars in tumour-bearing mice demonstrated an exceptionally high uptake in tumours with high EPR characteristics (14.8 - 21.7 %ID/g). Uptake of the star polymers in tumours with low EPR characteristics was significantly lower (P<0.001), suggesting passive tumour accumulation of the nanostars via the EPR effect. Survival of mice treated with high dose 177Lu-labelled star polymers was significantly higher than survival of mice treated with lower therapy doses or control mice (P=0.001), demonstrating the utility of the 177Lu-labelled star polymers as platforms for endoradiotherapy. Conclusion: Our work highlights the potential of star polymers as probes for the molecular imaging of cancer tissue or for the passive delivery of radionuclides for endoradiotherapy. Their high functionalisability and high tumour accumulation emphasises their versatility as powerful tools for nanomedicine.
Collapse
|
32
|
Bayat N, McOrist N, Ariotti N, Lai M, Sia KC, Li Y, Grace JL, Quinn JF, Whittaker MR, Kavallaris M, Davis TP, Lock RB. Thiol-Reactive Star Polymers Functionalized with Short Ethoxy-Containing Moieties Exhibit Enhanced Uptake in Acute Lymphoblastic Leukemia Cells. Int J Nanomedicine 2019; 14:9795-9808. [PMID: 31853178 PMCID: PMC6914812 DOI: 10.2147/ijn.s220326] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2019] [Accepted: 11/16/2019] [Indexed: 01/27/2023] Open
Abstract
Purpose Directing nanoparticles to cancer cells without using antibodies is of great interest. Subtle changes to the surface chemistry of nanoparticles can significantly affect their biological fate, including their propensity to associate with different cell populations. For instance, nanoparticles functionalized with thiol-reactive groups can potentially enhance association with cells that over-express cell-surface thiol groups. The potential of such an approach for enhancing drug delivery for childhood acute lymphoblastic leukemia (ALL) cells has not been investigated. Herein, we investigate the impact of thiol-reactive star polymers on the cellular association and the mechanisms of uptake of the nanoparticles. Methods We prepared fluorescently labeled star polymers functionalized with an mPEG brush corona and pyridyl disulfide to examine how reactivity to exofacial thiols impacts cellular association with ALL cells. We also studied how variations to the mPEG brush composition could potentially be used as a secondary method for controlling the extent of cell association. Specifically, we examined how the inclusion of shorter diethylene glycol brush moieties into the nanoparticle corona could be used to further influence cell association. Results Star polymers incorporating both thiol-reactive and diethylene glycol brush moieties exhibited the highest cellular association, followed by those functionalized solely with thiol reactive groups compared to control nanoparticles in T and B pediatric ALL patient-derived xenografts harvested from the spleens and bone marrow of immunodeficient mice. Transfection of cells with an early endosomal marker and imaging with correlative light and electron microscopy confirmed cellular uptake. Endocytosis inhibitors revealed dynamin-dependent clathrin-mediated endocytosis as the main uptake pathway for all the star polymers. Conclusion Thiol-reactive star polymers having an mPEG brush corona that includes a proportion of diethylene glycol brush moieties represent a potential strategy for improved leukemia cell delivery.
Collapse
Affiliation(s)
- Narges Bayat
- Leukemia Biology Program, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.,School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Nathan McOrist
- Leukemia Biology Program, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia
| | - Nicholas Ariotti
- Electron Microscope Unit, Mark Wainwright Analytical Centre, Chemical Sciences Building, University of New South Wales, Sydney, NSW, Australia.,School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia
| | - May Lai
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Keith Cs Sia
- Leukemia Biology Program, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.,School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| | - Yuhuan Li
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - James L Grace
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia
| | - Maria Kavallaris
- School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.,Tumor Biology and Targeting Program, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.,Australian Centre for Nanomedicine, ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of New South Wales, Sydney, NSW, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.,Department of Chemistry, University of Warwick, Coventry, UK.,Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Richard B Lock
- Leukemia Biology Program, Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.,School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia
| |
Collapse
|
33
|
Ramírez-García PD, Retamal JS, Shenoy P, Imlach W, Sykes M, Truong N, Constandil L, Pelissier T, Nowell CJ, Khor SY, Layani LM, Lumb C, Poole DP, Lieu T, Stewart GD, Mai QN, Jensen DD, Latorre R, Scheff NN, Schmidt BL, Quinn JF, Whittaker MR, Veldhuis NA, Davis TP, Bunnett NW. A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain. Nat Nanotechnol 2019; 14:1150-1159. [PMID: 31686009 PMCID: PMC7765343 DOI: 10.1038/s41565-019-0568-x] [Citation(s) in RCA: 85] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/22/2018] [Accepted: 10/02/2019] [Indexed: 05/11/2023]
Abstract
Nanoparticle-mediated drug delivery is especially useful for targets within endosomes because of the endosomal transport mechanisms of many nanomedicines within cells. Here, we report the design of a pH-responsive, soft polymeric nanoparticle for the targeting of acidified endosomes to precisely inhibit endosomal signalling events leading to chronic pain. In chronic pain, the substance P (SP) neurokinin 1 receptor (NK1R) redistributes from the plasma membrane to acidified endosomes, where it signals to maintain pain. Therefore, the NK1R in endosomes provides an important target for pain relief. The pH-responsive nanoparticles enter cells by clathrin- and dynamin-dependent endocytosis and accumulate in NK1R-containing endosomes. Following intrathecal injection into rodents, the nanoparticles, containing the FDA-approved NK1R antagonist aprepitant, inhibit SP-induced activation of spinal neurons and thus prevent pain transmission. Treatment with the nanoparticles leads to complete and persistent relief from nociceptive, inflammatory and neuropathic nociception and offers a much-needed non-opioid treatment option for chronic pain.
Collapse
Affiliation(s)
- Paulina D Ramírez-García
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Jeffri S Retamal
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Priyank Shenoy
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Wendy Imlach
- Monash Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia
| | - Matthew Sykes
- Monash Biomedicine Discovery Institute, Monash University, Melbourne, Victoria, Australia
| | - Nghia Truong
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Luis Constandil
- Laboratory of Neurobiology, Center for the Development of Nanoscience and Nanotechnology (CEDENNA), University of Santiago de Chile, Santiago, Chile
| | - Teresa Pelissier
- Laboratory of Neurobiology, Center for the Development of Nanoscience and Nanotechnology (CEDENNA), University of Santiago de Chile, Santiago, Chile
| | - Cameron J Nowell
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Song Y Khor
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Louis M Layani
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Chris Lumb
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Daniel P Poole
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - TinaMarie Lieu
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Gregory D Stewart
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
| | - Quynh N Mai
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Dane D Jensen
- Departments of Surgery and Pharmacology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University in the City of New York, New York , NY, USA
| | - Rocco Latorre
- Departments of Surgery and Pharmacology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University in the City of New York, New York , NY, USA
| | - Nicole N Scheff
- Bluestone Centre for Clinical Research, New York University College of Dentistry, New York, NY, USA
| | - Brian L Schmidt
- Bluestone Centre for Clinical Research, New York University College of Dentistry, New York, NY, USA
| | - John F Quinn
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Michael R Whittaker
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia
| | - Nicholas A Veldhuis
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia.
| | - Thomas P Davis
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia.
- Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane, Queensland, Australia.
| | - Nigel W Bunnett
- Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
- Australian Research Council Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Parkville, Victoria, Australia.
- Departments of Surgery and Pharmacology, Columbia University Vagelos College of Physicians and Surgeons, Columbia University in the City of New York, New York , NY, USA.
- Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, Australia.
| |
Collapse
|
34
|
Grace JL, Amado M, Reid JC, Elliott AG, Landersdorfer CB, Truong NP, Kempe K, Cooper MA, Davis TP, Montembault V, Pascual S, Fontaine L, Velkov T, Quinn JF, Whittaker MR. An optimised Cu(0)-RDRP approach for the synthesis of lipidated oligomeric vinyl azlactone: toward a versatile antimicrobial materials screening platform. J Mater Chem B 2019; 7:6796-6809. [PMID: 31603181 DOI: 10.1039/c9tb01624d] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
This report details the synthesis of lipidated 2-vinyl-4,4-dimethyl-5-oxazolone (VDM) oligomers via an optimised Cu(0)-mediated reversible-deactivation radical polymerisation approach, and the use of these oligomers as a versatile functional platform for the rapid generation of antimicrobial materials. The relative amounts of CuBr2 and Me6TREN were optimised to allow the fast and controlled polymerisation of VDM. These conditions were then used with the initiators ethyl 2-bromoisobutyrate, dodecyl 2-bromoisobutyrate, and (R)-3-((2-bromo-2-methylpropanoyl)oxy)propane-1,2-diyl didodecanoate to synthesise a library of oligo(VDM) (degree of polymerisation = 10) with ethyl, dodecyl or diglyceride end-groups. Subsequently, ring-opening of the pendant oxazolone group with various amines (i.e., 2-(2-aminoethyl)-1,3-di-Boc-guanidine, 1-(3-aminopropyl)imidazole, N-Boc-ethylenediamine, or N,N-dimethylethylenediamine) expanded the library to give 12 functional oligomers incorporating different cationic and lipid elements. The antimicrobial activities of these oligomers were assessed against a palette of bacteria and fungi: i.e. Staphylococcus aureus, Escherichia coli, Candida albicans, and Cryptococcus neoformans. The oligomers generally exhibited the greatest activity against the fungus, C. neoformans, with a minimum inhibitory concentration of 1 μg mL-1 (comparable to the clinically approved antifungal fluconazole). To assess haemocompatibility, the oligomers were assayed against erythrocytes, with the primary amine or guanidine containing C12 and 2C12 oligomers exhibiting greater lysis against the red blood cells (HC10 values between 7.1 and 43 μg mL-1) than their imidazole and tertiary amine counterparts (HC10 of >217 μg mL-1). Oligomers showed the greatest selectivity for C. neoformans, with the C12- and 2C12-tertiary amine and C12-imidazole oligomers possessing the greatest selectivity of >54-109. These results demonstrate the utility of reactive oligomers for rapidly assessing structure-property relationships for antibacterial and antifungal materials.
Collapse
Affiliation(s)
- James L Grace
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. and Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Maite Amado
- Institute of Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Janet C Reid
- Australian Institute of Bioengineering and Nanotechnology, University of Queensland, St Lucia, Queensland 4072, Australia
| | - Alysha G Elliott
- Institute of Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Cornelia B Landersdorfer
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia and Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Nghia P Truong
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. and Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Kristian Kempe
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. and Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Matthew A Cooper
- Institute of Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. and Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia and Australian Institute of Bioengineering and Nanotechnology, University of Queensland, St Lucia, Queensland 4072, Australia
| | - Véronique Montembault
- Institut des Molécules et Matériaux du Mans, UMR 6283 CNRS - Le Mans Université, Av. O. Messiaen, 72085 Le Mans Cedex 9, France
| | - Sagrario Pascual
- Institut des Molécules et Matériaux du Mans, UMR 6283 CNRS - Le Mans Université, Av. O. Messiaen, 72085 Le Mans Cedex 9, France
| | - Laurent Fontaine
- Institut des Molécules et Matériaux du Mans, UMR 6283 CNRS - Le Mans Université, Av. O. Messiaen, 72085 Le Mans Cedex 9, France
| | - Tony Velkov
- Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC 3010, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. and Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia. and Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC 3052, Australia
| |
Collapse
|
35
|
Sulistio A, Mansfeld FM, Reyes-Ortega F, D’Souza AM, Ng SMY, Birkett S, Blencowe A, Qiao GG, Little CB, Shu CC, Bendele AM, Valade D, Donohue AC, Quinn JF, Whittaker MR, Davis TP, Tait RJ. Intra-articular Treatment of Osteoarthritis with Diclofenac-Conjugated Polymer Reduces Inflammation and Pain. ACS Appl Bio Mater 2019; 2:2822-2832. [DOI: 10.1021/acsabm.9b00232] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Adrian Sulistio
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
| | - Friederike M. Mansfeld
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
- Children’s Cancer Institute, Australian Centre for NanoMedicine and ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The University of New South Wales, Sydney, New South Wales 2052, Australia
| | - Felisa Reyes-Ortega
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
| | - Asha M. D’Souza
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
- Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| | - Sarah M. Y. Ng
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
- Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| | - Stephen Birkett
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
- Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| | - Anton Blencowe
- School of Pharmacy and Medical Sciences, University of South Australia, Mawson Lake, South Australia 5095, Australia
| | - Greg G. Qiao
- Department of Chemical and Biomolecular Engineering, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Christopher B. Little
- Raymond Purves Bone and Joint Research Laboratories, Kolling Institute, University of Sydney at Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
| | - Cindy C. Shu
- Raymond Purves Bone and Joint Research Laboratories, Kolling Institute, University of Sydney at Royal North Shore Hospital, St Leonards, New South Wales 2065, Australia
| | - Alison M. Bendele
- Bolder BioPATH Inc.,5541 Central Avenue, Suite 160, Boulder, Colorado 80301, United States
| | - David Valade
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
- Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| | - Andrew C. Donohue
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
- Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| | - John F. Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, 4072, Australia
| | - Russell J. Tait
- PolyActiva Pty Ltd., Level 9, 31 Queen Street, Melbourne, Victoria 3000, Australia
- Monash Institute of Pharmaceutical Sciences, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Royal Parade, Parkville, Victoria 3052, Australia
| |
Collapse
|
36
|
Yu SH, Patra M, Ferrari S, Ramirez Garcia P, Veldhuis NA, Kaminskas LM, Graham B, Quinn JF, Whittaker MR, Gasser G, Davis TP. Linker chemistry dictates the delivery of a phototoxic organometallic rhenium(i) complex to human cervical cancer cells from core crosslinked star polymer nanoparticles. J Mater Chem B 2018; 6:7805-7810. [PMID: 32255026 DOI: 10.1039/c8tb02464b] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We have investigated core-crosslinked star polymer nanoparticles designed with tunable release chemistries as potential nanocarriers for a photoactive Re(i) organometallic complex. The nanoparticles consisted of a brush poly(oligo-ethylene glycol)methyl ether acrylate (POEGA) corona and a cross-linked core of non-biodegradable N,N'-methylenebis(acrylamide) (MBAA) and either pentafluorophenyl acrylate (PFPA), 3-vinyl benzaldehyde (VBA) or diacetone acrylamide (DAAM). Each star was modified with an amine functionalized photodynamic agent (i.e. a rhenium(i) organometallic complex) resulting in the formation of either a stable amide bond (POEGA-star-PFPA), or hydrolytically labile aldimine (POEGA-star-VBA) or ketimine bonds (POEGA-star-DAAM). These materials revealed linker dependent photo- and cytotoxicity when tested in vitro against non-cancerous lung fibroblast MRC-5 cells and HeLa human cervical cancer cells: the toxicity results correlated with final intracellular Re concentrations.
Collapse
Affiliation(s)
- Sul Hwa Yu
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Grace JL, Schneider-Futschik EK, Elliott AG, Amado M, Truong NP, Cooper MA, Li J, Davis TP, Quinn JF, Velkov T, Whittaker MR. Exploiting Macromolecular Design To Optimize the Antibacterial Activity of Alkylated Cationic Oligomers. Biomacromolecules 2018; 19:4629-4640. [PMID: 30359516 DOI: 10.1021/acs.biomac.8b01317] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
There is growing interest in synthetic polymers which co-opt the structural features of naturally occurring antimicrobial peptides. However, our understanding of how macromolecular architecture affects antibacterial activity remains limited. To address this, we investigated whether varying architectures of a series of block and statistical co-oligomers influenced antibacterial and hemolytic activity. Cu(0)-mediated polymerization was used to synthesize oligomers constituting 2-(Boc-amino)ethyl acrylate units and either diethylene glycol ethyl ether acrylate (DEGEEA) or poly(ethylene glycol) methyl ether acrylate units with varying macromolecular architecture; subsequent deprotection produced primary amine functional oligomers. Further guanylation provided an additional series of antimicrobial candidates. Both chemical composition and macromolecular architecture were shown to affect antimicrobial activity. A broad spectrum antibacterial oligomer (containing guanidine moieties and DEGEEA units) was identified that possessed promising activity (MIC = 2 μg mL-1) toward both Gram-negative and Gram-positive bacteria. Bacterial membrane permeabilization was identified as an important contributor to the mechanism of action.
Collapse
Affiliation(s)
- James L Grace
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia
| | - Elena K Schneider-Futschik
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences , The University of Melbourne , Parkville , VIC 3010 , Australia
| | - Alysha G Elliott
- Institute of Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia
| | - Maite Amado
- Institute of Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia
| | - Nghia P Truong
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia
| | - Matthew A Cooper
- Institute of Molecular Biosciences , The University of Queensland , Brisbane , QLD 4072 , Australia
| | - Jian Li
- Monash Biomedicine Discovery Institute, Department of Microbiology , Monash University , Clayton , Victoria 3800 , Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Department of Chemistry , Warwick University , Gibbet Hill , Coventry , CV4 7AL , U.K
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia
| | - Tony Velkov
- Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Department of Pharmacology & Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences , The University of Melbourne , Parkville , VIC 3010 , Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia.,Drug Delivery, Disposition and Dynamics Theme, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Pde , Parkville , VIC 3052 , Australia
| |
Collapse
|
38
|
Qiao R, Esser L, Fu C, Zhang C, Hu J, Ramírez-Arcía P, Li Y, Quinn JF, Whittaker MR, Whittaker AK, Davis TP. Bioconjugation and Fluorescence Labeling of Iron Oxide Nanoparticles Grafted with Bromomaleimide-Terminal Polymers. Biomacromolecules 2018; 19:4423-4429. [PMID: 30350948 DOI: 10.1021/acs.biomac.8b01282] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Iron oxide nanoparticles have been widely applied in biomedical applications for their unique physical properties. Despite the relatively mature synthetic approaches for iron oxide nanoparticles, surface modification strategies for obtaining particles with satisfactory biofunctionality are still urgently needed to meet the challenge of nanomedicine. Herein, we report a surface modification and biofunctionalization strategy for iron oxide-based magnetic nanoparticles based on a dibromomaleimide (DBM)-terminated polymer with brushed polyethylene glycol (PEG) chains. PEG acrylate and phosphonate monomers, serving as antibiofouling and surface anchoring compartments for iron oxide nanoparticles, were incorporated utilizing a novel DBM containing reversible addition-fragmentation chain transfer (RAFT) agent. The particles prepared through this new surface architecture possessed high colloidal stability in a physiological buffer and the capacity of covalent conjugation with biomolecules for targeting. Cell tracking of the molecular probes was achieved concomitantly by exploiting DBM conjugation-induced fluorescence of the nanoparticles.
Collapse
Affiliation(s)
- Ruirui Qiao
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville VIC 3052 , Australia
| | - Lars Esser
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville VIC 3052 , Australia
| | | | | | - Jinming Hu
- CAS Key Laboratory of Soft Matter Chemistry, Department of Polymer Science and Engineering , University of Science and Technology of China , Hefei , Anhui 230026 , China
| | - Paulina Ramírez-Arcía
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville VIC 3052 , Australia
| | - Yuhuan Li
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville VIC 3052 , Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville VIC 3052 , Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville VIC 3052 , Australia
| | | | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences , Monash University , 381 Royal Parade , Parkville VIC 3052 , Australia.,Department of Chemistry , University of Warwick , Gibbet Hill , Coventry CV4 7AL , United Kingdom
| |
Collapse
|
39
|
Zhang Q, Wang S, Qiao R, Whittaker MR, Quinn JF, Davis TP, Li H. Recent Advances in Magnetic Nanoparticle-based Molecular Probes for Hepatocellular Carcinoma Diagnosis and Therapy. Curr Pharm Des 2018; 24:2432-2437. [DOI: 10.2174/1381612824666180516111939] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2018] [Revised: 05/03/2018] [Accepted: 05/15/2018] [Indexed: 11/22/2022]
Abstract
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, leading to the second
most likely cause of cancer-related deaths. Medical imaging is crucial in clinic for HCC screening and diagnosis.
Due to the relatively high special resolution and excellent sensitivity, magnetic resonance imaging (MRI) by
using magnetic nanoparticle-based contrast agents has been used so far in HCC imaging and staging, demonstrating
great potential and promising in vivo applications. This review focuses on the use of different magnetic
nanoparticles for construction of HCC nanoprobes for MR imaging and theranostic purpose.
Collapse
Affiliation(s)
- Qi Zhang
- Department of Radiology, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, You An Men Wai, Feng Tai District, Beijing 100069, China
| | - Sudan Wang
- Department of Radiology, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, You An Men Wai, Feng Tai District, Beijing 100069, China
| | - Ruirui Qiao
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
| | - John F. Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
| | - Hongjun Li
- Department of Radiology, Beijing Youan Hospital, Capital Medical University, No. 8, Xi Tou Tiao, You An Men Wai, Feng Tai District, Beijing 100069, China
| |
Collapse
|
40
|
Khor SY, Quinn JF, Whittaker MR, Truong NP, Davis TP. Controlling Nanomaterial Size and Shape for Biomedical Applications via Polymerization-Induced Self-Assembly. Macromol Rapid Commun 2018; 40:e1800438. [PMID: 30091816 DOI: 10.1002/marc.201800438] [Citation(s) in RCA: 101] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 07/13/2018] [Indexed: 11/06/2022]
Abstract
Rapid developments in the polymerization-induced self-assembly (PISA) technique have paved the way for the environmentally friendly production of nanoparticles with tunable size and shape for a diverse range of applications. In this feature article, the biomedical applications of PISA nanoparticles and the substantial progress made in controlling their size and shape are highlighted. In addition to early investigations into drug delivery, applications such as medical imaging, tissue culture, and blood cryopreservation are also described. Various parameters for controlling the morphology of PISA nanoparticles are discussed, including the degree of polymerization of the macro-CTA and core-forming polymers, the concentration of macro-CTA and core-forming monomers, the solid content of the final products, the solution pH, the thermoresponsitivity of the macro-CTA, the macro-CTA end group, and the initiator concentration. Finally, several limitations and challenges for the PISA technique that have been recently addressed, along with those that will require further efforts into the future, will be highlighted.
Collapse
Affiliation(s)
- Song Yang Khor
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Nghia P Truong
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia.,Department of Chemistry, University of Warwick, Gibbet Hill, Coventry, CV47AL, UK
| |
Collapse
|
41
|
Ivask A, Pilkington EH, Blin T, Käkinen A, Vija H, Visnapuu M, Quinn JF, Whittaker MR, Qiao R, Davis TP, Ke PC, Voelcker NH. Uptake and transcytosis of functionalized superparamagnetic iron oxide nanoparticles in an in vitro blood brain barrier model. Biomater Sci 2018; 6:314-323. [PMID: 29239410 DOI: 10.1039/c7bm01012e] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Two major hurdles in nanomedicine are the limited strategies for synthesizing stealth nanoparticles and the poor efficacy of the nanoparticles in translocating across the blood brain barrier (BBB). Here we examined the uptake and transcytosis of iron oxide nanoparticles (IONPs) grafted with biomimetic phosphorylcholine (PC) brushes in an in vitro BBB model system, and compared them with bare, PEG or PC-PEG mixture grafted IONPs. Hyperspectral imaging indicated IONP co-localization with cells. Quantitative analysis with total reflection X-ray fluorescence spectrometry showed that after 24 h, 78% of PC grafted, 68-69% of PEG or PC-PEG grafted, and 30% of bare IONPs were taken up by the BBB. Transcytosis of IONPs was time-dependent and after 24 h, 16-17% of PC or PC-PEG mixture grafted IONPs had passed the BBB model, significantly more than PEG grafted or bare IONPs. These findings point out that grafting of IONPs with PC is a viable strategy for improving the uptake and transcytosis of nanoparticles.
Collapse
Affiliation(s)
- Angela Ivask
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia, Mawson Lakes, SA, Australia
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Khor SY, Vu MN, Pilkington EH, Johnston APR, Whittaker MR, Quinn JF, Truong NP, Davis TP. Elucidating the Influences of Size, Surface Chemistry, and Dynamic Flow on Cellular Association of Nanoparticles Made by Polymerization-Induced Self-Assembly. Small 2018; 14:e1801702. [PMID: 30043521 DOI: 10.1002/smll.201801702] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Revised: 06/10/2018] [Indexed: 06/08/2023]
Abstract
The size and surface chemistry of nanoparticles dictate their interactions with biological systems. However, it remains unclear how these key physicochemical properties affect the cellular association of nanoparticles under dynamic flow conditions encountered in human vascular networks. Here, the facile synthesis of novel fluorescent nanoparticles with tunable sizes and surface chemistries and their association with primary human umbilical vein endothelial cells (HUVECs) is reported. First, a one-pot polymerization-induced self-assembly (PISA) methodology is developed to covalently incorporate a commercially available fluorescent dye into the nanoparticle core and tune nanoparticle size and surface chemistry. To characterize cellular association under flow, HUVECs are cultured onto the surface of a synthetic microvascular network embedded in a microfluidic device (SynVivo, INC). Interestingly, increasing the size of carboxylic acid-functionalized nanoparticles leads to higher cellular association under static conditions but lower cellular association under flow conditions, whereas increasing the size of tertiary amine-decorated nanoparticles results in a higher level of cellular association, under both static and flow conditions. These findings provide new insights into the interactions between polymeric nanomaterials and endothelial cells. Altogether, this work establishes innovative methods for the facile synthesis and biological characterization of polymeric nanomaterials for various potential applications.
Collapse
Affiliation(s)
- Song Yang Khor
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Mai N Vu
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Emily H Pilkington
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
- Department of Chemistry, University of Warwick, Gibbet Hill, Coventry, CV47AL, UK
| | - Angus P R Johnston
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Nghia P Truong
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia
- Department of Chemistry, University of Warwick, Gibbet Hill, Coventry, CV47AL, UK
| |
Collapse
|
43
|
Ly J, Li Y, Vu MN, Moffat BA, Jack KS, Quinn JF, Whittaker MR, Davis TP. Nano-assemblies of cationic mPEG brush block copolymers with gadolinium polyoxotungstate [Gd(W 5O 18) 2] 9- form stable, high relaxivity MRI contrast agents. Nanoscale 2018; 10:7270-7280. [PMID: 29632934 DOI: 10.1039/c8nr01544a] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Polyoxometalates (POMs) incorporating paramagnetic ions, such as gadolinium, show promise as contrast agents for application in magnetic resonance imaging (MRI). Specifically, [Gd(W5O18)2]9- (denoted as GdWO) has been reported to have a higher relaxivity than commercially available contrast agents, but it's clinical utility has been limited by the intrinsic instability of POMs at physiological pH (7.4). In the current report we present a stability study on neat GdWO and nano-assemblies of block copolymers with GdWO in the pH range 5.0-7.4 to assess their suitability as MRI contrast agents. Neat GdWO only maintained structural stability between pH 5.4 and 6.4, and demonstrated poor MRI contrast at pH 7.4. To address this pH instability, GdWO was self-assembled with cationic mPEG brush block copolymers containing 20 or 40 units derived from the cationic monomer, 2-dimethylaminoethyl methacrylate (DMAEMA). Nano-assemblies with different charge ratios were synthesised and characterised according to their size, stability, contrasting properties and toxicity. The longitudinal relaxivity (r1) of the nano-assemblies was found to be dependent on the charge ratio, but not on the length of the cationic polymer block. Further investigation of PDMAEMA20 nano-assemblies demonstrated that they were stable over the pH range 5.0-7.4, exhibiting a higher r1 than either neat GdWO (2.77 s-1 mM-1) or clinical MRI contrast agent Gd-DTPA (4.1 s-1 mM-1) at pH 7.4. Importantly, the nano-assembly with the lowest charge ratio (0.2), showed the highest r1 (12.1 s-1 mM-1) whilst, stabilising GdWO over the pH range studied, eliciting low toxicity with MDA-MB231 cells.
Collapse
Affiliation(s)
- Joanne Ly
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Grace JL, Alcaraz N, Truong NP, Davis TP, Boyd BJ, Quinn JF, Whittaker MR. Lipidated polymers for the stabilization of cubosomes: nanostructured drug delivery vehicles. Chem Commun (Camb) 2018; 53:10552-10555. [PMID: 28890981 DOI: 10.1039/c7cc05842j] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Lipidated polymers, like their protein counterparts, may be useful in fields as diverse as biochemistry and drug delivery. As such, strategies for preparing lipidated polymers with defined molecular architecture are clearly warranted. Herein, we describe a broadly-applicable methodology for synthesizing such lipidated materials, and demonstrate how they can be applied to the preparation of nanostructured drug delivery vehicles.
Collapse
Affiliation(s)
- James L Grace
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia.
| | | | | | | | | | | | | |
Collapse
|
45
|
Truong NP, Zhang C, Nguyen TAH, Anastasaki A, Schulze MW, Quinn JF, Whittaker AK, Hawker CJ, Whittaker MR, Davis TP. Overcoming Surfactant-Induced Morphology Instability of Noncrosslinked Diblock Copolymer Nano-Objects Obtained by RAFT Emulsion Polymerization. ACS Macro Lett 2018; 7:159-165. [PMID: 35610912 DOI: 10.1021/acsmacrolett.7b00978] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
RAFT emulsion polymerization techniques including polymerization-induced self-assembly (PISA) and temperature-induced morphological transformation (TIMT) are widely used to produce noncrosslinked nano-objects with various morphologies. However, the worm, vesicle and lamellar morphologies produced by these techniques typically cannot tolerate the presence of added surfactants, thus limiting their potential applications. Herein we report the surfactant tolerance of noncrosslinked worms, vesicles, and lamellae prepared by RAFT emulsion polymerizations using poly(di(ethylene glycol) ethyl ether methacrylate-co-N-(2-hydroxypropyl) methacrylamide) (P(DEGMA-co-HPMA)) as a macromolecular chain transfer agent (macro-CTA). Significantly, these P(DEGMA-co-HPMA) nanoparticles are highly stable in concentrated solutions of surfactants (e.g., sodium dodecyl sulfate (SDS)). We also demonstrate that the surfactant tolerance is related to the limited binding of SDS to the main-chain of the P(DEGMA-co-HPMA) macro-CTA constituting the particle shell. This work provides new insight into the interactions between surfactants and thermoresponsive copolymers and expands the scope of RAFT emulsion polymerization techniques for the preparation of noncrosslinked and surfactant-tolerant nanomaterials.
Collapse
Affiliation(s)
- Nghia P Truong
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | | | | | - Athina Anastasaki
- Materials Research Laboratory, University of California, Santa Barbara, California 93106, United States
| | - Morgan W Schulze
- Materials Research Laboratory, University of California, Santa Barbara, California 93106, United States
| | - John F Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | | | - Craig J Hawker
- Materials Research Laboratory, University of California, Santa Barbara, California 93106, United States
| | - Michael R Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Thomas P Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
- Department of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom
| |
Collapse
|
46
|
Esser L, Lengkeek NA, Moffat BA, Vu MN, Greguric I, Quinn JF, Davis TP, Whittaker MR. A tunable one-pot three-component synthesis of an125I and Gd-labelled star polymer nanoparticle for hybrid imaging with MRI and nuclear medicine. Polym Chem 2018. [DOI: 10.1039/c8py00621k] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Bimodal radioiodine/Gd labelled polymeric nanoparticles prepared using a versatile one-step three-component click reaction.
Collapse
Affiliation(s)
- Lars Esser
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Nigel A. Lengkeek
- Australian Nuclear Science and Technology Organisation (ANSTO)
- Kirrawee DC
- Australia
| | | | - Mai N. Vu
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Ivan Greguric
- Australian Nuclear Science and Technology Organisation (ANSTO)
- Kirrawee DC
- Australia
| | - John F. Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology
- Monash Institute of Pharmaceutical Sciences
- Monash University
- Parkville
- Australia
| |
Collapse
|
47
|
Urquhart MC, Ercole F, Whittaker MR, Boyd BJ, Davis TP, Quinn JF. Recent advances in the delivery of hydrogen sulfide via a macromolecular approach. Polym Chem 2018. [DOI: 10.1039/c8py00938d] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
This mini review highlights recent advances in the design of macromolecular materials that can deliver hydrogen sulfide either spontaneously or in response to chemical and physical triggers.
Collapse
Affiliation(s)
- Matthew C. Urquhart
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Drug Delivery
- Disposition and Dynamics Theme
- Monash Institute of Pharmaceutical Sciences
- Monash University
| | - Francesca Ercole
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Drug Delivery
- Disposition and Dynamics Theme
- Monash Institute of Pharmaceutical Sciences
- Monash University
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Drug Delivery
- Disposition and Dynamics Theme
- Monash Institute of Pharmaceutical Sciences
- Monash University
| | - Ben J. Boyd
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Drug Delivery
- Disposition and Dynamics Theme
- Monash Institute of Pharmaceutical Sciences
- Monash University
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Drug Delivery
- Disposition and Dynamics Theme
- Monash Institute of Pharmaceutical Sciences
- Monash University
| | - John F. Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology
- Drug Delivery
- Disposition and Dynamics Theme
- Monash Institute of Pharmaceutical Sciences
- Monash University
| |
Collapse
|
48
|
Pilkington E, Lai M, Ge X, Stanley WJ, Wang B, Wang M, Kakinen A, Sani MA, Whittaker MR, Gurzov EN, Ding F, Quinn JF, Davis TP, Ke PC. Star Polymers Reduce Islet Amyloid Polypeptide Toxicity via Accelerated Amyloid Aggregation. Biomacromolecules 2017; 18:4249-4260. [PMID: 29035554 PMCID: PMC5729549 DOI: 10.1021/acs.biomac.7b01301] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 10/13/2017] [Indexed: 01/20/2023]
Abstract
Protein aggregation into amyloid fibrils is a ubiquitous phenomenon across the spectrum of neurodegenerative disorders and type 2 diabetes. A common strategy against amyloidogenesis is to minimize the populations of toxic oligomers and protofibrils by inhibiting protein aggregation with small molecules or nanoparticles. However, melanin synthesis in nature is realized by accelerated protein fibrillation to circumvent accumulation of toxic intermediates. Accordingly, we designed and demonstrated the use of star-shaped poly(2-hydroxyethyl acrylate) (PHEA) nanostructures for promoting aggregation while ameliorating the toxicity of human islet amyloid polypeptide (IAPP), the peptide involved in glycemic control and the pathology of type 2 diabetes. The binding of PHEA elevated the β-sheet content in IAPP aggregates while rendering a new morphology of "stelliform" amyloids originating from the polymers. Atomistic molecular dynamics simulations revealed that the PHEA arms served as rodlike scaffolds for IAPP binding and subsequently accelerated IAPP aggregation by increased local peptide concentration. The tertiary structure of the star nanoparticles was found to be essential for driving the specific interactions required to impel the accelerated IAPP aggregation. This study sheds new light on the structure-toxicity relationship of IAPP and points to the potential of exploiting star polymers as a new class of therapeutic agents against amyloidogenesis.
Collapse
Affiliation(s)
- Emily
H. Pilkington
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - May Lai
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Xinwei Ge
- Department
of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States
| | - William J. Stanley
- St
Vincent’s Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia
- Department
of Medicine, St. Vincent’s Hospital, The University of Melbourne, Melbourne, Australia
| | - Bo Wang
- Department
of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States
| | - Miaoyi Wang
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Aleksandr Kakinen
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Marc-Antonie Sani
- School of
Chemistry, Bio21 Institute, The University
of Melbourne, 30 Flemington
Rd, Parkville, Victoria 3010, Australia
| | - Michael R. Whittaker
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Esteban N. Gurzov
- St
Vincent’s Institute of Medical Research, 9 Princes Street, Fitzroy, Victoria 3065, Australia
- Department
of Medicine, St. Vincent’s Hospital, The University of Melbourne, Melbourne, Australia
| | - Feng Ding
- Department
of Physics and Astronomy, Clemson University, Clemson, South Carolina 29634, United States
| | - John F. Quinn
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Thomas P. Davis
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
- Department
of Chemistry, University of Warwick, Gibbet Hill, Coventry CV4 7AL, United Kingdom
| | - Pu Chun Ke
- ARC
Centre of Excellence in Convergent Bio-Nano Science and Technology,
Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| |
Collapse
|
49
|
Liu Q, Hu J, Whittaker MR, Davis TP, Boyd BJ. Nitric oxide-sensing actuators for modulating structure in lipid-based liquid crystalline drug delivery systems. J Colloid Interface Sci 2017; 508:517-524. [DOI: 10.1016/j.jcis.2017.08.079] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 08/23/2017] [Accepted: 08/23/2017] [Indexed: 02/02/2023]
|
50
|
Kaga S, Truong NP, Esser L, Senyschyn D, Sanyal A, Sanyal R, Quinn JF, Davis TP, Kaminskas LM, Whittaker MR. Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared by Polymerization-Induced Self-Assembly. Biomacromolecules 2017; 18:3963-3970. [DOI: 10.1021/acs.biomac.7b00995] [Citation(s) in RCA: 73] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Sadik Kaga
- Drug
Delivery Disposition Dynamics, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, Victoria 3052, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Department
of Chemistry, Bogazici University, Istanbul 34342, Turkey
| | - Nghia P. Truong
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Lars Esser
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Danielle Senyschyn
- Drug
Delivery Disposition Dynamics, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, Victoria 3052, Australia
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Amitav Sanyal
- Department
of Chemistry, Bogazici University, Istanbul 34342, Turkey
| | - Rana Sanyal
- Department
of Chemistry, Bogazici University, Istanbul 34342, Turkey
| | - John F. Quinn
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Thomas P. Davis
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
- Department
of Chemistry, University of Warwick, Coventry CV4 7AL, United Kingdom
| | - Lisa M. Kaminskas
- Drug
Delivery Disposition Dynamics, Monash Institute of Pharmaceutical
Sciences, Monash University, Parkville, Victoria 3052, Australia
- School
of Biomedical Sciences, University of Queensland, St. Lucia, Queensland 7052, Australia
| | - Michael R. Whittaker
- ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| |
Collapse
|